KR20140027947A - Beautiful-skin-promoting agent and use thereof - Google Patents
Beautiful-skin-promoting agent and use thereof Download PDFInfo
- Publication number
- KR20140027947A KR20140027947A KR1020137026500A KR20137026500A KR20140027947A KR 20140027947 A KR20140027947 A KR 20140027947A KR 1020137026500 A KR1020137026500 A KR 1020137026500A KR 20137026500 A KR20137026500 A KR 20137026500A KR 20140027947 A KR20140027947 A KR 20140027947A
- Authority
- KR
- South Korea
- Prior art keywords
- skin
- acid
- promoter
- resveratrol
- extract
- Prior art date
Links
- 235000019136 lipoic acid Nutrition 0.000 claims abstract description 74
- AGBQKNBQESQNJD-UHFFFAOYSA-N alpha-Lipoic acid Natural products OC(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-N 0.000 claims abstract description 65
- 239000000284 extract Substances 0.000 claims abstract description 65
- AGBQKNBQESQNJD-SSDOTTSWSA-N (R)-lipoic acid Chemical compound OC(=O)CCCC[C@@H]1CCSS1 AGBQKNBQESQNJD-SSDOTTSWSA-N 0.000 claims abstract description 64
- 229960002663 thioctic acid Drugs 0.000 claims abstract description 63
- 240000001548 Camellia japonica Species 0.000 claims abstract description 44
- 102000008186 Collagen Human genes 0.000 claims abstract description 44
- 108010035532 Collagen Proteins 0.000 claims abstract description 44
- 229920001436 collagen Polymers 0.000 claims abstract description 44
- LUKBXSAWLPMMSZ-OWOJBTEDSA-N Trans-resveratrol Chemical compound C1=CC(O)=CC=C1\C=C\C1=CC(O)=CC(O)=C1 LUKBXSAWLPMMSZ-OWOJBTEDSA-N 0.000 claims abstract description 43
- 229940016667 resveratrol Drugs 0.000 claims abstract description 43
- QNVSXXGDAPORNA-UHFFFAOYSA-N Resveratrol Natural products OC1=CC=CC(C=CC=2C=C(O)C(O)=CC=2)=C1 QNVSXXGDAPORNA-UHFFFAOYSA-N 0.000 claims abstract description 42
- 239000000203 mixture Substances 0.000 claims abstract description 42
- 235000021283 resveratrol Nutrition 0.000 claims abstract description 42
- 235000018597 common camellia Nutrition 0.000 claims abstract description 41
- 230000017531 blood circulation Effects 0.000 claims abstract description 38
- 230000003796 beauty Effects 0.000 claims abstract description 37
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 34
- 238000000034 method Methods 0.000 claims abstract description 23
- 239000004480 active ingredient Substances 0.000 claims abstract description 15
- 230000001737 promoting effect Effects 0.000 claims abstract description 14
- 239000000419 plant extract Substances 0.000 claims abstract description 11
- 239000002537 cosmetic Substances 0.000 claims abstract description 9
- 238000001035 drying Methods 0.000 claims abstract description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 48
- 150000002632 lipids Chemical class 0.000 claims description 36
- 238000000576 coating method Methods 0.000 claims description 33
- 239000011248 coating agent Substances 0.000 claims description 31
- 239000000843 powder Substances 0.000 claims description 29
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 29
- 239000003795 chemical substances by application Substances 0.000 claims description 19
- 108010010803 Gelatin Proteins 0.000 claims description 16
- 239000008273 gelatin Substances 0.000 claims description 16
- 229920000159 gelatin Polymers 0.000 claims description 16
- 235000019322 gelatine Nutrition 0.000 claims description 16
- 235000011852 gelatine desserts Nutrition 0.000 claims description 16
- 239000002245 particle Substances 0.000 claims description 16
- 239000013078 crystal Substances 0.000 claims description 15
- 235000013305 food Nutrition 0.000 claims description 13
- 150000002148 esters Chemical class 0.000 claims description 12
- 150000003839 salts Chemical class 0.000 claims description 11
- 229920000858 Cyclodextrin Polymers 0.000 claims description 10
- 241000196324 Embryophyta Species 0.000 claims description 10
- 229930182490 saponin Natural products 0.000 claims description 9
- 150000007949 saponins Chemical class 0.000 claims description 9
- 235000017709 saponins Nutrition 0.000 claims description 9
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 claims description 9
- FQWLMRXWKZGLFI-YVYUXZJTSA-N (-)-trans-epsilon-viniferin Chemical compound C1=CC(O)=CC=C1\C=C\C1=CC(O)=CC2=C1[C@@H](C=1C=C(O)C=C(O)C=1)[C@H](C=1C=CC(O)=CC=1)O2 FQWLMRXWKZGLFI-YVYUXZJTSA-N 0.000 claims description 8
- 239000011888 foil Substances 0.000 claims description 8
- 150000001408 amides Chemical class 0.000 claims description 7
- 235000009754 Vitis X bourquina Nutrition 0.000 claims description 5
- 235000012333 Vitis X labruscana Nutrition 0.000 claims description 5
- 235000014787 Vitis vinifera Nutrition 0.000 claims description 5
- IZFHEQBZOYJLPK-UHFFFAOYSA-N dihydrolipoic acid Chemical compound OC(=O)CCCCC(S)CCS IZFHEQBZOYJLPK-UHFFFAOYSA-N 0.000 claims description 5
- 241000219094 Vitaceae Species 0.000 claims description 4
- FQWLMRXWKZGLFI-UHFFFAOYSA-N cis epsilon-viniferine Natural products C1=CC(O)=CC=C1C=CC1=CC(O)=CC2=C1C(C=1C=C(O)C=C(O)C=1)C(C=1C=CC(O)=CC=1)O2 FQWLMRXWKZGLFI-UHFFFAOYSA-N 0.000 claims description 4
- SXRAUGAFMDOHKN-UHFFFAOYSA-N epsilon-viniferin Natural products CC1(Oc2cc(O)cc(C=Cc3ccc(O)cc3)c2C1(C)c4cc(O)cc(O)c4)c5ccc(O)cc5 SXRAUGAFMDOHKN-UHFFFAOYSA-N 0.000 claims description 4
- 235000021021 grapes Nutrition 0.000 claims description 4
- 229930182470 glycoside Natural products 0.000 claims description 3
- 150000002338 glycosides Chemical class 0.000 claims description 3
- 241000209507 Camellia Species 0.000 claims 2
- 240000006365 Vitis vinifera Species 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract description 7
- 239000004129 EU approved improving agent Substances 0.000 abstract description 5
- 230000003247 decreasing effect Effects 0.000 abstract description 5
- 210000003491 skin Anatomy 0.000 description 88
- 230000000694 effects Effects 0.000 description 32
- 239000000126 substance Substances 0.000 description 21
- -1 etc.) Chemical compound 0.000 description 20
- 239000003814 drug Substances 0.000 description 19
- 239000000047 product Substances 0.000 description 18
- 238000002156 mixing Methods 0.000 description 17
- 239000002994 raw material Substances 0.000 description 17
- 238000012360 testing method Methods 0.000 description 17
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 15
- 239000000706 filtrate Substances 0.000 description 15
- 229940014259 gelatin Drugs 0.000 description 15
- 230000035755 proliferation Effects 0.000 description 15
- 229940079593 drug Drugs 0.000 description 14
- 238000007796 conventional method Methods 0.000 description 13
- 239000000463 material Substances 0.000 description 13
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 12
- 210000004027 cell Anatomy 0.000 description 12
- 235000014113 dietary fatty acids Nutrition 0.000 description 11
- 238000000605 extraction Methods 0.000 description 11
- 239000000194 fatty acid Substances 0.000 description 11
- 229930195729 fatty acid Natural products 0.000 description 11
- 239000003921 oil Substances 0.000 description 11
- 235000019198 oils Nutrition 0.000 description 11
- 210000001626 skin fibroblast Anatomy 0.000 description 11
- 210000001519 tissue Anatomy 0.000 description 11
- 241001465754 Metazoa Species 0.000 description 10
- 239000002609 medium Substances 0.000 description 10
- 239000002904 solvent Substances 0.000 description 10
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 9
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 9
- 150000001298 alcohols Chemical class 0.000 description 9
- 238000002360 preparation method Methods 0.000 description 9
- 239000001993 wax Substances 0.000 description 9
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 8
- 239000002253 acid Substances 0.000 description 8
- 239000002775 capsule Substances 0.000 description 8
- 239000003925 fat Substances 0.000 description 8
- 235000019197 fats Nutrition 0.000 description 8
- 210000002950 fibroblast Anatomy 0.000 description 8
- 238000002844 melting Methods 0.000 description 8
- 230000008018 melting Effects 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 239000003826 tablet Substances 0.000 description 8
- AGBQKNBQESQNJD-ZETCQYMHSA-N (S)-lipoic acid Chemical compound OC(=O)CCCC[C@H]1CCSS1 AGBQKNBQESQNJD-ZETCQYMHSA-N 0.000 description 7
- 239000000654 additive Substances 0.000 description 7
- 239000007788 liquid Substances 0.000 description 7
- 238000004519 manufacturing process Methods 0.000 description 7
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 6
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 6
- 239000009429 Ginkgo biloba extract Substances 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 6
- 230000009471 action Effects 0.000 description 6
- 229940008396 carrot extract Drugs 0.000 description 6
- 235000013399 edible fruits Nutrition 0.000 description 6
- 239000008187 granular material Substances 0.000 description 6
- 229920002674 hyaluronan Polymers 0.000 description 6
- 229960003160 hyaluronic acid Drugs 0.000 description 6
- 159000000000 sodium salts Chemical class 0.000 description 6
- 230000037303 wrinkles Effects 0.000 description 6
- IZFHEQBZOYJLPK-SSDOTTSWSA-N (R)-dihydrolipoic acid Chemical compound OC(=O)CCCC[C@@H](S)CCS IZFHEQBZOYJLPK-SSDOTTSWSA-N 0.000 description 5
- RWTCSOPMUDGZQL-UHFFFAOYSA-N Camelliasaponin C2 Natural products CC=C(/C)C(=O)OC1CC(C)(C)CC2C3=CCC4C5(C)CCC(OC6OC(CO)C(O)C(OC7OCC(O)C(O)C7OC8OC(CO)C(O)C(O)C8O)C6OC9OC(CO)C(O)C(O)C9O)C(C)(CO)C5CCC4(C)C3(C)CC(O)C12CO RWTCSOPMUDGZQL-UHFFFAOYSA-N 0.000 description 5
- 241000219095 Vitis Species 0.000 description 5
- YDGQDJXYFVWQDO-UHFFFAOYSA-N camelliasaponin B1 Natural products CC=C(/C)C(=O)OC1CC(C)(C)CC2C3=CCC4C5(C)CCC(OC6OC(CO)C(O)C(OC7OCC(O)C(O)C7OC8OC(CO)C(O)C(O)C8O)C6OC9OC(CO)C(O)C(O)C9O)C(C)(C=O)C5CCC4(C)C3(C)CC(O)C12CO YDGQDJXYFVWQDO-UHFFFAOYSA-N 0.000 description 5
- MGTOPLIWMNGFCQ-UHFFFAOYSA-N camelliasaponin B2 Natural products O=CC1(C)C2CCC3(C)C4(C)CC(O)C5(CO)C(OC(=O)C(C)=CC)CC(C)(C)CC5C4=CCC3C2(C)CCC1OC(C1OC2C(C(O)C(O)C(CO)O2)O)OC(C(O)=O)C(O)C1OC1OCC(O)C(O)C1OC1OC(CO)C(O)C(O)C1O MGTOPLIWMNGFCQ-UHFFFAOYSA-N 0.000 description 5
- 150000004665 fatty acids Chemical class 0.000 description 5
- 238000004128 high performance liquid chromatography Methods 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 4
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 4
- WNWHHMBRJJOGFJ-UHFFFAOYSA-N 16-methylheptadecan-1-ol Chemical compound CC(C)CCCCCCCCCCCCCCCO WNWHHMBRJJOGFJ-UHFFFAOYSA-N 0.000 description 4
- MPDGHEJMBKOTSU-YKLVYJNSSA-N 18beta-glycyrrhetic acid Chemical compound C([C@H]1C2=CC(=O)[C@H]34)[C@@](C)(C(O)=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](O)C1(C)C MPDGHEJMBKOTSU-YKLVYJNSSA-N 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 4
- 240000007594 Oryza sativa Species 0.000 description 4
- 235000007164 Oryza sativa Nutrition 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 4
- 241001062811 Stewartia malacodendron Species 0.000 description 4
- 150000007513 acids Chemical class 0.000 description 4
- 235000013361 beverage Nutrition 0.000 description 4
- 159000000007 calcium salts Chemical class 0.000 description 4
- YKPUWZUDDOIDPM-SOFGYWHQSA-N capsaicin Chemical compound COC1=CC(CNC(=O)CCCC\C=C\C(C)C)=CC=C1O YKPUWZUDDOIDPM-SOFGYWHQSA-N 0.000 description 4
- 229910052799 carbon Inorganic materials 0.000 description 4
- MWKFXSUHUHTGQN-UHFFFAOYSA-N decan-1-ol Chemical compound CCCCCCCCCCO MWKFXSUHUHTGQN-UHFFFAOYSA-N 0.000 description 4
- 235000015872 dietary supplement Nutrition 0.000 description 4
- NOPFSRXAKWQILS-UHFFFAOYSA-N docosan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCCCO NOPFSRXAKWQILS-UHFFFAOYSA-N 0.000 description 4
- 230000037406 food intake Effects 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 238000005194 fractionation Methods 0.000 description 4
- 239000007902 hard capsule Substances 0.000 description 4
- 239000000178 monomer Substances 0.000 description 4
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 4
- 239000003960 organic solvent Substances 0.000 description 4
- 229920000642 polymer Polymers 0.000 description 4
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 4
- 238000010992 reflux Methods 0.000 description 4
- 235000009566 rice Nutrition 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 230000037394 skin elasticity Effects 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- HLZKNKRTKFSKGZ-UHFFFAOYSA-N tetradecan-1-ol Chemical compound CCCCCCCCCCCCCCO HLZKNKRTKFSKGZ-UHFFFAOYSA-N 0.000 description 4
- KRGSIOSNSSCAMH-IHGNYCBKSA-N (2r,3s,6r)-6-[[(4r,4ar,6as,6bs,8ar,12as,14ar,14br)-8-hydroxy-4,8a-bis(hydroxymethyl)-4,6a,6b,11,11,14b-hexamethyl-9-[(e)-2-methylbut-2-enoyl]oxy-1,2,3,4a,5,6,7,8,9,10,12,12a,14,14a-tetradecahydropicen-3-yl]oxy]-4-[(2s,3s,4r,5s)-4,5-dihydroxy-3-[(2s,3s,4r) Chemical compound O([C@H]1[C@H](O)[C@@H](O)CO[C@H]1OC1[C@H](O)[C@@H](O[C@H](C1O[C@H]1C(C(O)C(O)C(CO)O1)O)OC1CC[C@]2(C)[C@H]3CC=C4[C@@H]5CC(C)(C)CC([C@@]5(C(O)C[C@@]4(C)[C@@]3(C)CC[C@H]2[C@@]1(CO)C)CO)OC(=O)C(/C)=C/C)C(O)=O)[C@@H]1OC(CO)C(O)[C@@H](O)[C@@H]1O KRGSIOSNSSCAMH-IHGNYCBKSA-N 0.000 description 3
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 description 3
- IZFHEQBZOYJLPK-ZETCQYMHSA-N (S)-dihydrolipoic acid Chemical compound OC(=O)CCCC[C@H](S)CCS IZFHEQBZOYJLPK-ZETCQYMHSA-N 0.000 description 3
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 3
- 241000283690 Bos taurus Species 0.000 description 3
- KTCJGPRMIOCILW-UXZWGIKGSA-N Camelliasaponin A1 Natural products CC=C(C)C(=O)O[C@H]1CC(C)(C)C[C@H]2C3=CC[C@@H]4[C@@]5(C)CC[C@H](O[C@@H]6O[C@@H]([C@@H](O)[C@H](O[C@@H]7OC[C@H](O)[C@H](O)[C@H]7O[C@@H]8O[C@H](CO)[C@@H](O)[C@H](O)[C@H]8O)[C@H]6O[C@@H]9O[C@H](CO)[C@H](O)[C@H](O)[C@H]9O)C(=O)O)C(C)(C)[C@@H]5CC[C@@]4(C)[C@]3(C)C[C@@H](O)[C@@]12CO KTCJGPRMIOCILW-UXZWGIKGSA-N 0.000 description 3
- 229920001353 Dextrin Polymers 0.000 description 3
- 239000004375 Dextrin Substances 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- 229930182558 Sterol Natural products 0.000 description 3
- 235000006886 Zingiber officinale Nutrition 0.000 description 3
- 244000273928 Zingiber officinale Species 0.000 description 3
- 230000000996 additive effect Effects 0.000 description 3
- MGTOPLIWMNGFCQ-PGGKNCGUSA-N camelliasaponin b2 Chemical compound O=CC1(C)C2CCC3(C)C4(C)CC(O)C5(CO)C(OC(=O)C(/C)=C/C)CC(C)(C)CC5C4=CCC3C2(C)CCC1OC(C1OC2C(C(O)C(O)C(CO)O2)O)OC(C(O)=O)C(O)C1OC1OCC(O)C(O)C1OC1OC(CO)C(O)C(O)C1O MGTOPLIWMNGFCQ-PGGKNCGUSA-N 0.000 description 3
- 125000004432 carbon atom Chemical group C* 0.000 description 3
- 229960004203 carnitine Drugs 0.000 description 3
- 239000003638 chemical reducing agent Substances 0.000 description 3
- 230000006866 deterioration Effects 0.000 description 3
- 235000019425 dextrin Nutrition 0.000 description 3
- 235000020673 eicosapentaenoic acid Nutrition 0.000 description 3
- 229940088598 enzyme Drugs 0.000 description 3
- 210000002615 epidermis Anatomy 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 235000008397 ginger Nutrition 0.000 description 3
- NLDDIKRKFXEWBK-AWEZNQCLSA-N gingerol Chemical compound CCCCC[C@H](O)CC(=O)CCC1=CC=C(O)C(OC)=C1 NLDDIKRKFXEWBK-AWEZNQCLSA-N 0.000 description 3
- 235000002780 gingerol Nutrition 0.000 description 3
- JZLXEKNVCWMYHI-UHFFFAOYSA-N gingerol Natural products CCCCC(O)CC(=O)CCC1=CC=C(O)C(OC)=C1 JZLXEKNVCWMYHI-UHFFFAOYSA-N 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 235000011187 glycerol Nutrition 0.000 description 3
- 235000013402 health food Nutrition 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 229910052500 inorganic mineral Inorganic materials 0.000 description 3
- 239000011707 mineral Substances 0.000 description 3
- 235000010755 mineral Nutrition 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 235000012149 noodles Nutrition 0.000 description 3
- 150000003904 phospholipids Chemical class 0.000 description 3
- 229940068196 placebo Drugs 0.000 description 3
- 239000000902 placebo Substances 0.000 description 3
- 159000000001 potassium salts Chemical class 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 239000012264 purified product Substances 0.000 description 3
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 235000021067 refined food Nutrition 0.000 description 3
- 238000007665 sagging Methods 0.000 description 3
- 235000015067 sauces Nutrition 0.000 description 3
- 239000007901 soft capsule Substances 0.000 description 3
- 238000001694 spray drying Methods 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 150000003432 sterols Chemical class 0.000 description 3
- 235000003702 sterols Nutrition 0.000 description 3
- 150000005846 sugar alcohols Polymers 0.000 description 3
- 210000005253 yeast cell Anatomy 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- OILXMJHPFNGGTO-UHFFFAOYSA-N (22E)-(24xi)-24-methylcholesta-5,22-dien-3beta-ol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(C)C(C)C)C1(C)CC2 OILXMJHPFNGGTO-UHFFFAOYSA-N 0.000 description 2
- MGTOPLIWMNGFCQ-UOPXLPJJSA-N (2s,3s,4s,5r,6r)-6-[[(3s,4s,4ar,6ar,6bs,8r,8ar,9s,12as,14ar,14br)-4-formyl-8-hydroxy-8a-(hydroxymethyl)-4,6a,6b,11,11,14b-hexamethyl-9-[(z)-2-methylbut-2-enoyl]oxy-1,2,3,4a,5,6,7,8,9,10,12,12a,14,14a-tetradecahydropicen-3-yl]oxy]-4-[(2s,3r,4s,5s)-4,5-dihy Chemical compound O([C@@H]1[C@@H](O)[C@@H](O)CO[C@H]1O[C@H]1[C@H](O)[C@H](O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O1)O)O[C@H]1CC[C@]2(C)[C@H]3CC=C4[C@@H]5CC(C)(C)C[C@@H]([C@@]5([C@H](O)C[C@@]4(C)[C@]3(C)CC[C@H]2[C@@]1(C=O)C)CO)OC(=O)C(\C)=C/C)C(O)=O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O MGTOPLIWMNGFCQ-UOPXLPJJSA-N 0.000 description 2
- ULQISTXYYBZJSJ-UHFFFAOYSA-N 12-hydroxyoctadecanoic acid Chemical compound CCCCCCC(O)CCCCCCCCCCC(O)=O ULQISTXYYBZJSJ-UHFFFAOYSA-N 0.000 description 2
- XDOFQFKRPWOURC-UHFFFAOYSA-N 16-methylheptadecanoic acid Chemical compound CC(C)CCCCCCCCCCCCCCC(O)=O XDOFQFKRPWOURC-UHFFFAOYSA-N 0.000 description 2
- OQMZNAMGEHIHNN-UHFFFAOYSA-N 7-Dehydrostigmasterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CC(CC)C(C)C)CCC33)C)C3=CC=C21 OQMZNAMGEHIHNN-UHFFFAOYSA-N 0.000 description 2
- 241000251468 Actinopterygii Species 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 2
- RVEWUBJVAHOGKA-WOYAITHZSA-N Arginine glutamate Chemical compound OC(=O)[C@@H](N)CCC(O)=O.OC(=O)[C@@H](N)CCCNC(N)=N RVEWUBJVAHOGKA-WOYAITHZSA-N 0.000 description 2
- 241000972773 Aulopiformes Species 0.000 description 2
- JMGZEFIQIZZSBH-UHFFFAOYSA-N Bioquercetin Natural products CC1OC(OCC(O)C2OC(OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5)C(O)C2O)C(O)C(O)C1O JMGZEFIQIZZSBH-UHFFFAOYSA-N 0.000 description 2
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 2
- 235000006467 Camellia japonica Nutrition 0.000 description 2
- 240000006846 Camellia reticulata Species 0.000 description 2
- KTCJGPRMIOCILW-PHROOHHUSA-N Camelliasaponin A2 Natural products O=C(O[C@@H]1[C@]2(CO)[C@H](O)C[C@@]3(C)[C@@]4(C)[C@@H]([C@]5(C)[C@H](C(C)(C)[C@@H](O[C@H]6[C@H](O[C@H]7[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O7)[C@@H](O[C@H]7[C@H](O[C@H]8[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O8)[C@@H](O)[C@@H](O)CO7)[C@H](O)[C@@H](C(=O)O)O6)CC5)CC4)CC=C3[C@@H]2CC(C)(C)C1)/C(=C\C)/C KTCJGPRMIOCILW-PHROOHHUSA-N 0.000 description 2
- KRGSIOSNSSCAMH-QPAGQQEASA-N Camelliasaponin C1 Natural products O([C@@H]1[C@@H](O)[C@@H](O)CO[C@H]1O[C@H]1[C@H](O)[C@H](O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O1)O)O[C@H]1CC[C@]2(C)[C@H]3CC=C4[C@@H]5CC(C)(C)C[C@@H]([C@@]5([C@H](O)C[C@@]4(C)[C@]3(C)CC[C@H]2[C@@]1(CO)C)CO)OC(=O)C(/C)=C/C)C(O)=O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O KRGSIOSNSSCAMH-QPAGQQEASA-N 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 2
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 2
- 239000004386 Erythritol Substances 0.000 description 2
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 2
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 2
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 2
- 229920000855 Fucoidan Polymers 0.000 description 2
- 239000006000 Garlic extract Substances 0.000 description 2
- 229930186217 Glycolipid Natural products 0.000 description 2
- MPDGHEJMBKOTSU-UHFFFAOYSA-N Glycyrrhetinsaeure Natural products C12C(=O)C=C3C4CC(C)(C(O)=O)CCC4(C)CCC3(C)C1(C)CCC1C2(C)CCC(O)C1(C)C MPDGHEJMBKOTSU-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 229920000057 Mannan Polymers 0.000 description 2
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 2
- 235000019482 Palm oil Nutrition 0.000 description 2
- 102000035195 Peptidases Human genes 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 108010073771 Soybean Proteins Proteins 0.000 description 2
- 241000282887 Suidae Species 0.000 description 2
- 241001122767 Theaceae Species 0.000 description 2
- 241000276707 Tilapia Species 0.000 description 2
- 229930003270 Vitamin B Natural products 0.000 description 2
- 229930003427 Vitamin E Natural products 0.000 description 2
- 229920002494 Zein Polymers 0.000 description 2
- 108010055615 Zein Proteins 0.000 description 2
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 description 2
- 239000003463 adsorbent Substances 0.000 description 2
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 2
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 2
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- 229960004246 arginine glutamate Drugs 0.000 description 2
- 108010013835 arginine glutamate Proteins 0.000 description 2
- 235000013871 bee wax Nutrition 0.000 description 2
- 239000012166 beeswax Substances 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- CDQSJQSWAWPGKG-UHFFFAOYSA-N butane-1,1-diol Chemical compound CCCC(O)O CDQSJQSWAWPGKG-UHFFFAOYSA-N 0.000 description 2
- 235000012970 cakes Nutrition 0.000 description 2
- HEZVPSGPLFBHPM-YSURURNPSA-N camelliasaponin a2 Chemical compound CC1(C)C2CCC3(C)C4(C)CC(O)C5(CO)C(OC(=O)C(/C)=C/C)CC(C)(C)CC5C4=CCC3C2(C)CCC1OC(C(C1O)OC2C(C(O)C(O)C(CO)O2)O)OC(C(O)=O)C1OC1OCC(O)C(O)C1OC1OC(CO)C(O)C(O)C1O HEZVPSGPLFBHPM-YSURURNPSA-N 0.000 description 2
- KRGSIOSNSSCAMH-PGGKNCGUSA-N camelliasaponin c1 Chemical compound OCC1(C)C2CCC3(C)C4(C)CC(O)C5(CO)C(OC(=O)C(/C)=C/C)CC(C)(C)CC5C4=CCC3C2(C)CCC1OC(C1OC2C(C(O)C(O)C(CO)O2)O)OC(C(O)=O)C(O)C1OC1OCC(O)C(O)C1OC1OC(CO)C(O)C(O)C1O KRGSIOSNSSCAMH-PGGKNCGUSA-N 0.000 description 2
- 235000017663 capsaicin Nutrition 0.000 description 2
- 229960002504 capsaicin Drugs 0.000 description 2
- 239000007963 capsule composition Substances 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 241001233037 catfish Species 0.000 description 2
- 229960000541 cetyl alcohol Drugs 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 244000192963 common camellia Species 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 239000008162 cooking oil Substances 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 230000008025 crystallization Effects 0.000 description 2
- GHVNFZFCNZKVNT-UHFFFAOYSA-N decanoic acid Chemical compound CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 238000005238 degreasing Methods 0.000 description 2
- 210000004207 dermis Anatomy 0.000 description 2
- UKMSUNONTOPOIO-UHFFFAOYSA-N docosanoic acid Chemical compound CCCCCCCCCCCCCCCCCCCCCC(O)=O UKMSUNONTOPOIO-UHFFFAOYSA-N 0.000 description 2
- 229960000735 docosanol Drugs 0.000 description 2
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 2
- 229960003720 enoxolone Drugs 0.000 description 2
- 238000006911 enzymatic reaction Methods 0.000 description 2
- IVTMALDHFAHOGL-UHFFFAOYSA-N eriodictyol 7-O-rutinoside Natural products OC1C(O)C(O)C(C)OC1OCC1C(O)C(O)C(O)C(OC=2C=C3C(C(C(O)=C(O3)C=3C=C(O)C(O)=CC=3)=O)=C(O)C=2)O1 IVTMALDHFAHOGL-UHFFFAOYSA-N 0.000 description 2
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 2
- 235000019414 erythritol Nutrition 0.000 description 2
- 229940009714 erythritol Drugs 0.000 description 2
- 210000002744 extracellular matrix Anatomy 0.000 description 2
- 238000000855 fermentation Methods 0.000 description 2
- 230000004151 fermentation Effects 0.000 description 2
- 235000019688 fish Nutrition 0.000 description 2
- HVQAJTFOCKOKIN-UHFFFAOYSA-N flavonol Natural products O1C2=CC=CC=C2C(=O)C(O)=C1C1=CC=CC=C1 HVQAJTFOCKOKIN-UHFFFAOYSA-N 0.000 description 2
- 150000002216 flavonol derivatives Chemical class 0.000 description 2
- 235000011957 flavonols Nutrition 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 2
- 235000020706 garlic extract Nutrition 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 235000020708 ginger extract Nutrition 0.000 description 2
- 229940002508 ginger extract Drugs 0.000 description 2
- 229940106580 ginkgo biloba leaf extract Drugs 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 125000005456 glyceride group Chemical group 0.000 description 2
- 229960004949 glycyrrhizic acid Drugs 0.000 description 2
- 235000019410 glycyrrhizin Nutrition 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 2
- 230000003301 hydrolyzing effect Effects 0.000 description 2
- VKOBVWXKNCXXDE-UHFFFAOYSA-N icosanoic acid Chemical compound CCCCCCCCCCCCCCCCCCCC(O)=O VKOBVWXKNCXXDE-UHFFFAOYSA-N 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 239000003456 ion exchange resin Substances 0.000 description 2
- 229920003303 ion-exchange polymer Polymers 0.000 description 2
- ZXEKIIBDNHEJCQ-UHFFFAOYSA-N isobutanol Chemical compound CC(C)CO ZXEKIIBDNHEJCQ-UHFFFAOYSA-N 0.000 description 2
- CJWQYWQDLBZGPD-UHFFFAOYSA-N isoflavone Natural products C1=C(OC)C(OC)=CC(OC)=C1C1=COC2=C(C=CC(C)(C)O3)C3=C(OC)C=C2C1=O CJWQYWQDLBZGPD-UHFFFAOYSA-N 0.000 description 2
- 235000008696 isoflavones Nutrition 0.000 description 2
- 235000015110 jellies Nutrition 0.000 description 2
- 239000008274 jelly Substances 0.000 description 2
- 235000021374 legumes Nutrition 0.000 description 2
- 159000000003 magnesium salts Chemical class 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 235000013372 meat Nutrition 0.000 description 2
- 150000004702 methyl esters Chemical class 0.000 description 2
- 229940043348 myristyl alcohol Drugs 0.000 description 2
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 2
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 2
- 229960003512 nicotinic acid Drugs 0.000 description 2
- 235000001968 nicotinic acid Nutrition 0.000 description 2
- 239000011664 nicotinic acid Substances 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 2
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 2
- 230000001590 oxidative effect Effects 0.000 description 2
- 239000002540 palm oil Substances 0.000 description 2
- SECPZKHBENQXJG-FPLPWBNLSA-N palmitoleic acid Chemical compound CCCCCC\C=C/CCCCCCCC(O)=O SECPZKHBENQXJG-FPLPWBNLSA-N 0.000 description 2
- 229940055726 pantothenic acid Drugs 0.000 description 2
- 235000019161 pantothenic acid Nutrition 0.000 description 2
- 239000011713 pantothenic acid Substances 0.000 description 2
- 239000006072 paste Substances 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000002062 proliferating effect Effects 0.000 description 2
- 238000010298 pulverizing process Methods 0.000 description 2
- FDRQPMVGJOQVTL-UHFFFAOYSA-N quercetin rutinoside Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 FDRQPMVGJOQVTL-UHFFFAOYSA-N 0.000 description 2
- 235000020748 rosemary extract Nutrition 0.000 description 2
- 229940092258 rosemary extract Drugs 0.000 description 2
- 239000001233 rosmarinus officinalis l. extract Substances 0.000 description 2
- IKGXIBQEEMLURG-BKUODXTLSA-N rutin Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@@H]1OC[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-BKUODXTLSA-N 0.000 description 2
- ALABRVAAKCSLSC-UHFFFAOYSA-N rutin Natural products CC1OC(OCC2OC(O)C(O)C(O)C2O)C(O)C(O)C1OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5 ALABRVAAKCSLSC-UHFFFAOYSA-N 0.000 description 2
- 235000005493 rutin Nutrition 0.000 description 2
- 229960004555 rutoside Drugs 0.000 description 2
- 229940119485 safflower extract Drugs 0.000 description 2
- 235000019515 salmon Nutrition 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 229940001941 soy protein Drugs 0.000 description 2
- 235000013555 soy sauce Nutrition 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 229940012831 stearyl alcohol Drugs 0.000 description 2
- PJANXHGTPQOBST-UHFFFAOYSA-N stilbene Chemical class C=1C=CC=CC=1C=CC1=CC=CC=C1 PJANXHGTPQOBST-UHFFFAOYSA-N 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- UIERETOOQGIECD-ONEGZZNKSA-N tiglic acid Chemical compound C\C=C(/C)C(O)=O UIERETOOQGIECD-ONEGZZNKSA-N 0.000 description 2
- LLZRNZOLAXHGLL-UHFFFAOYSA-J titanic acid Chemical compound O[Ti](O)(O)O LLZRNZOLAXHGLL-UHFFFAOYSA-J 0.000 description 2
- 229940042585 tocopherol acetate Drugs 0.000 description 2
- 150000003626 triacylglycerols Chemical class 0.000 description 2
- 239000008513 turmeric extract Substances 0.000 description 2
- 229940052016 turmeric extract Drugs 0.000 description 2
- 235000020240 turmeric extract Nutrition 0.000 description 2
- 239000000052 vinegar Substances 0.000 description 2
- 235000021419 vinegar Nutrition 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 235000019156 vitamin B Nutrition 0.000 description 2
- 239000011720 vitamin B Substances 0.000 description 2
- 235000019165 vitamin E Nutrition 0.000 description 2
- 229940046009 vitamin E Drugs 0.000 description 2
- 239000011709 vitamin E Substances 0.000 description 2
- 229940093612 zein Drugs 0.000 description 2
- 239000005019 zein Substances 0.000 description 2
- RQOCXCFLRBRBCS-UHFFFAOYSA-N (22E)-cholesta-5,7,22-trien-3beta-ol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CCC(C)C)CCC33)C)C3=CC=C21 RQOCXCFLRBRBCS-UHFFFAOYSA-N 0.000 description 1
- DVSZKTAMJJTWFG-SKCDLICFSA-N (2e,4e,6e,8e,10e,12e)-docosa-2,4,6,8,10,12-hexaenoic acid Chemical compound CCCCCCCCC\C=C\C=C\C=C\C=C\C=C\C=C\C(O)=O DVSZKTAMJJTWFG-SKCDLICFSA-N 0.000 description 1
- DSEKYWAQQVUQTP-XEWMWGOFSA-N (2r,4r,4as,6as,6as,6br,8ar,12ar,14as,14bs)-2-hydroxy-4,4a,6a,6b,8a,11,11,14a-octamethyl-2,4,5,6,6a,7,8,9,10,12,12a,13,14,14b-tetradecahydro-1h-picen-3-one Chemical compound C([C@H]1[C@]2(C)CC[C@@]34C)C(C)(C)CC[C@]1(C)CC[C@]2(C)[C@H]4CC[C@@]1(C)[C@H]3C[C@@H](O)C(=O)[C@@H]1C DSEKYWAQQVUQTP-XEWMWGOFSA-N 0.000 description 1
- LPLVUJXQOOQHMX-MOGLOQIBSA-N (2s,3s,4s,5r,6r)-6-[(2r,3r,4s,5s,6s)-2-[[(3s,4ar,6ar,6bs,8as,11s,12ar,14ar,14bs)-11-carboxy-4,4,6a,6b,8a,11,14b-heptamethyl-14-oxo-2,3,4a,5,6,7,8,9,10,12,12a,14a-dodecahydro-1h-picen-3-yl]oxy]-6-carboxy-4,5-dihydroxyoxan-3-yl]oxy-3,4,5-trihydroxyoxane-2-c Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-MOGLOQIBSA-N 0.000 description 1
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- RKFYYCKIHVEWHX-YOBICRQBSA-N (E)-trans-miyabenol C Chemical compound C1=CC(O)=CC=C1\C=C\C1=CC(O)=CC2=C1[C@H](C=1C=3[C@H]([C@@H](OC=3C=C(O)C=1)C=1C=CC(O)=CC=1)C=1C=C(O)C=C(O)C=1)[C@@H](C=1C=CC(O)=CC=1)O2 RKFYYCKIHVEWHX-YOBICRQBSA-N 0.000 description 1
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- PORPENFLTBBHSG-MGBGTMOVSA-N 1,2-dihexadecanoyl-sn-glycerol-3-phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(O)=O)OC(=O)CCCCCCCCCCCCCCC PORPENFLTBBHSG-MGBGTMOVSA-N 0.000 description 1
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 description 1
- JMGCAHRKIVCLFW-UHFFFAOYSA-N 1-O-Galloylcastalagin Natural products Oc1cc(cc(O)c1O)C(=O)OC2C3OC(=O)c4c2c(O)c(O)c(O)c4c5c(O)c(O)c(O)c6c5C(=O)OC3C7OC(=O)c8cc(O)c(O)c(O)c8c9c(O)c(O)c(O)cc9C(=O)OCC7OC(=O)c%10cc(O)c(O)c(O)c6%10 JMGCAHRKIVCLFW-UHFFFAOYSA-N 0.000 description 1
- ZAUYNCUCMJDAHW-UHFFFAOYSA-N 1-ethenylpyrrolidin-2-one;hydrogen peroxide;molecular iodine Chemical compound OO.II.C=CN1CCCC1=O ZAUYNCUCMJDAHW-UHFFFAOYSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- 229940114072 12-hydroxystearic acid Drugs 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- GICIECWTEWJCRE-UHFFFAOYSA-N 3,4,4,7-tetramethyl-2,3-dihydro-1h-naphthalene Chemical compound CC1=CC=C2C(C)(C)C(C)CCC2=C1 GICIECWTEWJCRE-UHFFFAOYSA-N 0.000 description 1
- AZKSAVLVSZKNRD-UHFFFAOYSA-M 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide Chemical compound [Br-].S1C(C)=C(C)N=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=CC=C1 AZKSAVLVSZKNRD-UHFFFAOYSA-M 0.000 description 1
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 description 1
- GZJLLYHBALOKEX-UHFFFAOYSA-N 6-Ketone, O18-Me-Ussuriedine Natural products CC=CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O GZJLLYHBALOKEX-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 201000004384 Alopecia Diseases 0.000 description 1
- 229920001450 Alpha-Cyclodextrin Polymers 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 235000021357 Behenic acid Nutrition 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 240000002791 Brassica napus Species 0.000 description 1
- 235000004977 Brassica sinapistrum Nutrition 0.000 description 1
- DPUOLQHDNGRHBS-UHFFFAOYSA-N Brassidinsaeure Natural products CCCCCCCCC=CCCCCCCCCCCCC(O)=O DPUOLQHDNGRHBS-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241001328788 Camellia nitidissima Species 0.000 description 1
- 241001343472 Camellia pitardii Species 0.000 description 1
- 241001343471 Camellia saluenensis Species 0.000 description 1
- 239000005632 Capric acid (CAS 334-48-5) Substances 0.000 description 1
- 239000005635 Caprylic acid (CAS 124-07-2) Substances 0.000 description 1
- 240000004160 Capsicum annuum Species 0.000 description 1
- 235000008534 Capsicum annuum var annuum Nutrition 0.000 description 1
- 235000007862 Capsicum baccatum Nutrition 0.000 description 1
- 241000251730 Chondrichthyes Species 0.000 description 1
- 229920001287 Chondroitin sulfate Polymers 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 244000241257 Cucumis melo Species 0.000 description 1
- 235000015510 Cucumis melo subsp melo Nutrition 0.000 description 1
- 241000252233 Cyprinus carpio Species 0.000 description 1
- 208000019505 Deglutition disease Diseases 0.000 description 1
- 206010013786 Dry skin Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 239000004278 EU approved seasoning Substances 0.000 description 1
- 102000016942 Elastin Human genes 0.000 description 1
- 108010014258 Elastin Proteins 0.000 description 1
- AFSDNFLWKVMVRB-UHFFFAOYSA-N Ellagic acid Chemical compound OC1=C(O)C(OC2=O)=C3C4=C2C=C(O)C(O)=C4OC(=O)C3=C1 AFSDNFLWKVMVRB-UHFFFAOYSA-N 0.000 description 1
- ATJXMQHAMYVHRX-CPCISQLKSA-N Ellagic acid Natural products OC1=C(O)[C@H]2OC(=O)c3cc(O)c(O)c4OC(=O)C(=C1)[C@H]2c34 ATJXMQHAMYVHRX-CPCISQLKSA-N 0.000 description 1
- 229920002079 Ellagic acid Polymers 0.000 description 1
- 241000283074 Equus asinus Species 0.000 description 1
- DNVPQKQSNYMLRS-NXVQYWJNSA-N Ergosterol Natural products CC(C)[C@@H](C)C=C[C@H](C)[C@H]1CC[C@H]2C3=CC=C4C[C@@H](O)CC[C@]4(C)[C@@H]3CC[C@]12C DNVPQKQSNYMLRS-NXVQYWJNSA-N 0.000 description 1
- URXZXNYJPAJJOQ-UHFFFAOYSA-N Erucic acid Natural products CCCCCCC=CCCCCCCCCCCCC(O)=O URXZXNYJPAJJOQ-UHFFFAOYSA-N 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- 235000009419 Fagopyrum esculentum Nutrition 0.000 description 1
- 240000008620 Fagopyrum esculentum Species 0.000 description 1
- 235000016970 Fragaria moschata Nutrition 0.000 description 1
- 244000307700 Fragaria vesca Species 0.000 description 1
- 235000014828 Fragaria vesca ssp. americana Nutrition 0.000 description 1
- 235000012660 Fragaria virginiana Nutrition 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 241000276438 Gadus morhua Species 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 235000000885 Garcinia xanthochymus Nutrition 0.000 description 1
- 244000119461 Garcinia xanthochymus Species 0.000 description 1
- SDTOABMYDICPQU-UHFFFAOYSA-N Genkwanin Natural products C=1C(C)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(O)C=C1 SDTOABMYDICPQU-UHFFFAOYSA-N 0.000 description 1
- 229920001503 Glucan Polymers 0.000 description 1
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 description 1
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- 239000004378 Glycyrrhizin Substances 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- 240000002045 Guettarda speciosa Species 0.000 description 1
- 235000001287 Guettarda speciosa Nutrition 0.000 description 1
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- DZUKXCCSULKRJA-UHFFFAOYSA-N Isopratol Natural products C=1C(OC)=CC=C(C(C=2)=O)C=1OC=2C1=CC=C(O)C=C1 DZUKXCCSULKRJA-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241001147156 Lates niloticus Species 0.000 description 1
- 239000005639 Lauric acid Substances 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 235000015429 Mirabilis expansa Nutrition 0.000 description 1
- 244000294411 Mirabilis expansa Species 0.000 description 1
- OBOUYBKGROJMIK-KOBVKWGYSA-N Miyabenol C Natural products Oc1ccc(C=Cc2cc(O)cc3O[C@H]([C@H](c4cc(O)c5O[C@@H]([C@@H](c6cc(O)cc(O)c6)c5c4)c7ccc(O)cc7)c23)c8ccc(O)cc8)cc1 OBOUYBKGROJMIK-KOBVKWGYSA-N 0.000 description 1
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 1
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 1
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 235000021319 Palmitoleic acid Nutrition 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 235000004347 Perilla Nutrition 0.000 description 1
- 244000124853 Perilla frutescens Species 0.000 description 1
- 241000286209 Phasianidae Species 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 241000508269 Psidium Species 0.000 description 1
- 229920001218 Pullulan Polymers 0.000 description 1
- 239000004373 Pullulan Substances 0.000 description 1
- 235000019484 Rapeseed oil Nutrition 0.000 description 1
- 235000019485 Safflower oil Nutrition 0.000 description 1
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- PJANXHGTPQOBST-VAWYXSNFSA-N Stilbene Natural products C=1C=CC=CC=1/C=C/C1=CC=CC=C1 PJANXHGTPQOBST-VAWYXSNFSA-N 0.000 description 1
- 241000272534 Struthio camelus Species 0.000 description 1
- 241000692569 Stylephorus chordatus Species 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 235000019486 Sunflower oil Nutrition 0.000 description 1
- 240000004584 Tamarindus indica Species 0.000 description 1
- 235000004298 Tamarindus indica Nutrition 0.000 description 1
- 244000299461 Theobroma cacao Species 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- HZYXFRGVBOPPNZ-UHFFFAOYSA-N UNPD88870 Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)=CCC(CC)C(C)C)C1(C)CC2 HZYXFRGVBOPPNZ-UHFFFAOYSA-N 0.000 description 1
- 235000004283 Vitis amurensis Nutrition 0.000 description 1
- 240000002503 Vitis amurensis Species 0.000 description 1
- 244000068697 Vitis rotundifolia Species 0.000 description 1
- 235000006359 Vitis rotundifolia var rotundifolia Nutrition 0.000 description 1
- 102000007544 Whey Proteins Human genes 0.000 description 1
- 108010046377 Whey Proteins Proteins 0.000 description 1
- FJJCIZWZNKZHII-UHFFFAOYSA-N [4,6-bis(cyanoamino)-1,3,5-triazin-2-yl]cyanamide Chemical compound N#CNC1=NC(NC#N)=NC(NC#N)=N1 FJJCIZWZNKZHII-UHFFFAOYSA-N 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000001361 adipic acid Substances 0.000 description 1
- 235000011037 adipic acid Nutrition 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 description 1
- 231100000360 alopecia Toxicity 0.000 description 1
- HFHDHCJBZVLPGP-RWMJIURBSA-N alpha-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO HFHDHCJBZVLPGP-RWMJIURBSA-N 0.000 description 1
- 229940043377 alpha-cyclodextrin Drugs 0.000 description 1
- 235000020661 alpha-linolenic acid Nutrition 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 235000021342 arachidonic acid Nutrition 0.000 description 1
- 229940114079 arachidonic acid Drugs 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 239000007640 basal medium Substances 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- OGBUMNBNEWYMNJ-UHFFFAOYSA-N batilol Chemical class CCCCCCCCCCCCCCCCCCOCC(O)CO OGBUMNBNEWYMNJ-UHFFFAOYSA-N 0.000 description 1
- 229940116226 behenic acid Drugs 0.000 description 1
- LGJMUZUPVCAVPU-UHFFFAOYSA-N beta-Sitostanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CC)C(C)C)C1(C)CC2 LGJMUZUPVCAVPU-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- HEZVPSGPLFBHPM-VROXFSQNSA-N camelliasaponin a1 Chemical compound CC1(C)C2CCC3(C)C4(C)CC(O)C5(CO)C(OC(=O)C(\C)=C/C)CC(C)(C)CC5C4=CCC3C2(C)CCC1OC(C(C1O)OC2C(C(O)C(O)C(CO)O2)O)OC(C(O)=O)C1OC1OCC(O)C(O)C1OC1OC(CO)C(O)C(O)C1O HEZVPSGPLFBHPM-VROXFSQNSA-N 0.000 description 1
- 239000004204 candelilla wax Substances 0.000 description 1
- 235000013868 candelilla wax Nutrition 0.000 description 1
- 229940073532 candelilla wax Drugs 0.000 description 1
- 239000001728 capsicum frutescens Substances 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 235000012730 carminic acid Nutrition 0.000 description 1
- 239000004203 carnauba wax Substances 0.000 description 1
- 235000013869 carnauba wax Nutrition 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 235000013330 chicken meat Nutrition 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 229940059329 chondroitin sulfate Drugs 0.000 description 1
- SECPZKHBENQXJG-UHFFFAOYSA-N cis-palmitoleic acid Natural products CCCCCCC=CCCCCCCCC(O)=O SECPZKHBENQXJG-UHFFFAOYSA-N 0.000 description 1
- 230000037319 collagen production Effects 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 235000014510 cooky Nutrition 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000010908 decantation Methods 0.000 description 1
- 238000004042 decolorization Methods 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 238000004332 deodorization Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 238000007599 discharging Methods 0.000 description 1
- 238000002845 discoloration Methods 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 235000020669 docosahexaenoic acid Nutrition 0.000 description 1
- KAUVQQXNCKESLC-UHFFFAOYSA-N docosahexaenoic acid (DHA) Natural products COC(=O)C(C)NOCC1=CC=CC=C1 KAUVQQXNCKESLC-UHFFFAOYSA-N 0.000 description 1
- LQZZUXJYWNFBMV-UHFFFAOYSA-N dodecan-1-ol Chemical compound CCCCCCCCCCCCO LQZZUXJYWNFBMV-UHFFFAOYSA-N 0.000 description 1
- 235000015071 dressings Nutrition 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 239000008157 edible vegetable oil Substances 0.000 description 1
- 230000009982 effect on human Effects 0.000 description 1
- 229960005135 eicosapentaenoic acid Drugs 0.000 description 1
- 229920002549 elastin Polymers 0.000 description 1
- 229960002852 ellagic acid Drugs 0.000 description 1
- 235000004132 ellagic acid Nutrition 0.000 description 1
- 229920001968 ellagitannin Polymers 0.000 description 1
- JMGCAHRKIVCLFW-CNWXVVPTSA-N ellagitannin Chemical compound OC1=C(O)C(O)=CC(C(=O)O[C@H]2C3=C4C(=O)O[C@@H]2[C@@H]2[C@@H]5OC(=O)C6=CC(O)=C(O)C(O)=C6C6=C(O)C(O)=C(O)C=C6C(=O)OC[C@H]5OC(=O)C5=CC(O)=C(O)C(O)=C5C=5C(O)=C(O)C(O)=C(C=5C(=O)O2)C4=C(O)C(O)=C3O)=C1 JMGCAHRKIVCLFW-CNWXVVPTSA-N 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- DNVPQKQSNYMLRS-SOWFXMKYSA-N ergosterol Chemical compound C1[C@@H](O)CC[C@]2(C)[C@H](CC[C@]3([C@H]([C@H](C)/C=C/[C@@H](C)C(C)C)CC[C@H]33)C)C3=CC=C21 DNVPQKQSNYMLRS-SOWFXMKYSA-N 0.000 description 1
- DPUOLQHDNGRHBS-KTKRTIGZSA-N erucic acid Chemical compound CCCCCCCC\C=C/CCCCCCCCCCCC(O)=O DPUOLQHDNGRHBS-KTKRTIGZSA-N 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 235000008524 evening primrose extract Nutrition 0.000 description 1
- 239000010475 evening primrose oil Substances 0.000 description 1
- 229940089020 evening primrose oil Drugs 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 235000021323 fish oil Nutrition 0.000 description 1
- 235000011194 food seasoning agent Nutrition 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 235000015203 fruit juice Nutrition 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 239000000417 fungicide Substances 0.000 description 1
- VZCCETWTMQHEPK-UHFFFAOYSA-N gamma-Linolensaeure Natural products CCCCCC=CCC=CCC=CCCCCC(O)=O VZCCETWTMQHEPK-UHFFFAOYSA-N 0.000 description 1
- VZCCETWTMQHEPK-QNEBEIHSSA-N gamma-linolenic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/CCCCC(O)=O VZCCETWTMQHEPK-QNEBEIHSSA-N 0.000 description 1
- 235000020664 gamma-linolenic acid Nutrition 0.000 description 1
- 229960002733 gamolenic acid Drugs 0.000 description 1
- JPMYFOBNRRGFNO-UHFFFAOYSA-N genkwanin Chemical compound C=1C(OC)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(O)C=C1 JPMYFOBNRRGFNO-UHFFFAOYSA-N 0.000 description 1
- 229940068052 ginkgo biloba extract Drugs 0.000 description 1
- 235000020686 ginkgo biloba extract Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- 235000015220 hamburgers Nutrition 0.000 description 1
- 235000021059 hard food Nutrition 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- IUJAMGNYPWYUPM-UHFFFAOYSA-N hentriacontane Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCC IUJAMGNYPWYUPM-UHFFFAOYSA-N 0.000 description 1
- WLTXBTSNYDYARD-UHFFFAOYSA-N hoduloside III Natural products OC1C(O)C(O)C(C)OC1OC1C(OC2C(C(O)C(O)C(CO)O2)O)C(O)COC1OC1C(C)(C)C(CCC2(C)C34CC5(C(C(CC(O5)C=C(C)C)(C)O)C4CCC42)OC3)C4(C)CC1 WLTXBTSNYDYARD-UHFFFAOYSA-N 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000012943 hotmelt Substances 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 238000009776 industrial production Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 235000008446 instant noodles Nutrition 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- YAQXGBBDJYBXKL-UHFFFAOYSA-N iron(2+);1,10-phenanthroline;dicyanide Chemical compound [Fe+2].N#[C-].N#[C-].C1=CN=C2C3=NC=CC=C3C=CC2=C1.C1=CN=C2C3=NC=CC=C3C=CC2=C1 YAQXGBBDJYBXKL-UHFFFAOYSA-N 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- GOMNOOKGLZYEJT-UHFFFAOYSA-N isoflavone Chemical compound C=1OC2=CC=CC=C2C(=O)C=1C1=CC=CC=C1 GOMNOOKGLZYEJT-UHFFFAOYSA-N 0.000 description 1
- 150000002515 isoflavone derivatives Chemical class 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 235000015094 jam Nutrition 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 229960004488 linolenic acid Drugs 0.000 description 1
- 239000000944 linseed oil Substances 0.000 description 1
- 235000021388 linseed oil Nutrition 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 235000021056 liquid food Nutrition 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- HCWCAKKEBCNQJP-UHFFFAOYSA-N magnesium orthosilicate Chemical compound [Mg+2].[Mg+2].[O-][Si]([O-])([O-])[O-] HCWCAKKEBCNQJP-UHFFFAOYSA-N 0.000 description 1
- 239000000391 magnesium silicate Substances 0.000 description 1
- 229910052919 magnesium silicate Inorganic materials 0.000 description 1
- 235000019792 magnesium silicate Nutrition 0.000 description 1
- 235000013310 margarine Nutrition 0.000 description 1
- 239000003264 margarine Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 239000008268 mayonnaise Substances 0.000 description 1
- 235000010746 mayonnaise Nutrition 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 210000002752 melanocyte Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- FAARLWTXUUQFSN-UHFFFAOYSA-N methylellagic acid Natural products O1C(=O)C2=CC(O)=C(O)C3=C2C2=C1C(OC)=C(O)C=C2C(=O)O3 FAARLWTXUUQFSN-UHFFFAOYSA-N 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000004200 microcrystalline wax Substances 0.000 description 1
- 235000019808 microcrystalline wax Nutrition 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 235000013536 miso Nutrition 0.000 description 1
- 239000011812 mixed powder Substances 0.000 description 1
- 239000012170 montan wax Substances 0.000 description 1
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 1
- 229950006780 n-acetylglucosamine Drugs 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- SLCVBVWXLSEKPL-UHFFFAOYSA-N neopentyl glycol Chemical compound OCC(C)(C)CO SLCVBVWXLSEKPL-UHFFFAOYSA-N 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 231100000862 numbness Toxicity 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 229960002446 octanoic acid Drugs 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000008008 oral excipient Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 235000019449 other food additives Nutrition 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000003346 palm kernel oil Substances 0.000 description 1
- 235000019865 palm kernel oil Nutrition 0.000 description 1
- 206010033675 panniculitis Diseases 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 229940116257 pepper extract Drugs 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 239000012169 petroleum derived wax Substances 0.000 description 1
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 1
- 150000008104 phosphatidylethanolamines Chemical class 0.000 description 1
- 150000003905 phosphatidylinositols Chemical class 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 230000003169 placental effect Effects 0.000 description 1
- 229920000223 polyglycerol Polymers 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
- 235000011962 puddings Nutrition 0.000 description 1
- 235000019423 pullulan Nutrition 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 1
- WBHHMMIMDMUBKC-QJWNTBNXSA-N ricinoleic acid Chemical compound CCCCCC[C@@H](O)C\C=C/CCCCCCCC(O)=O WBHHMMIMDMUBKC-QJWNTBNXSA-N 0.000 description 1
- FEUQNCSVHBHROZ-UHFFFAOYSA-N ricinoleic acid Natural products CCCCCCC(O[Si](C)(C)C)CC=CCCCCCCCC(=O)OC FEUQNCSVHBHROZ-UHFFFAOYSA-N 0.000 description 1
- 229960003656 ricinoleic acid Drugs 0.000 description 1
- 238000007788 roughening Methods 0.000 description 1
- 239000010979 ruby Substances 0.000 description 1
- 229910001750 ruby Inorganic materials 0.000 description 1
- 235000005713 safflower oil Nutrition 0.000 description 1
- 239000003813 safflower oil Substances 0.000 description 1
- 235000003441 saturated fatty acids Nutrition 0.000 description 1
- 150000004671 saturated fatty acids Chemical class 0.000 description 1
- 235000013580 sausages Nutrition 0.000 description 1
- 210000004761 scalp Anatomy 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 239000012176 shellac wax Substances 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 230000005808 skin problem Effects 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 235000014214 soft drink Nutrition 0.000 description 1
- 238000007711 solidification Methods 0.000 description 1
- 230000008023 solidification Effects 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- HCXVJBMSMIARIN-PHZDYDNGSA-N stigmasterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)/C=C/[C@@H](CC)C(C)C)[C@@]1(C)CC2 HCXVJBMSMIARIN-PHZDYDNGSA-N 0.000 description 1
- 229940032091 stigmasterol Drugs 0.000 description 1
- BFDNMXAIBMJLBB-UHFFFAOYSA-N stigmasterol Natural products CCC(C=CC(C)C1CCCC2C3CC=C4CC(O)CCC4(C)C3CCC12C)C(C)C BFDNMXAIBMJLBB-UHFFFAOYSA-N 0.000 description 1
- 235000016831 stigmasterol Nutrition 0.000 description 1
- 235000021286 stilbenes Nutrition 0.000 description 1
- 210000000434 stratum corneum Anatomy 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 210000004304 subcutaneous tissue Anatomy 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000002600 sunflower oil Substances 0.000 description 1
- 238000000194 supercritical-fluid extraction Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000003760 tallow Substances 0.000 description 1
- 229920001864 tannin Polymers 0.000 description 1
- 235000018553 tannin Nutrition 0.000 description 1
- 239000001648 tannin Substances 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- TUNFSRHWOTWDNC-HKGQFRNVSA-N tetradecanoic acid Chemical compound CCCCCCCCCCCCC[14C](O)=O TUNFSRHWOTWDNC-HKGQFRNVSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 235000018991 trans-resveratrol Nutrition 0.000 description 1
- 238000005809 transesterification reaction Methods 0.000 description 1
- 239000013638 trimer Substances 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 235000015192 vegetable juice Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000010497 wheat germ oil Substances 0.000 description 1
- 235000021119 whey protein Nutrition 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- 235000013618 yogurt Nutrition 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
- A61K8/65—Collagen; Gelatin; Keratin; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/18—Peptides; Protein hydrolysates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/82—Theaceae (Tea family), e.g. camellia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4875—Compounds of unknown constitution, e.g. material from plants or animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
Abstract
본 발명은 피부의 건조, 탄력 저하, 피부 거칠어짐 등의 피부 상태의 개선 및/또는 피부 미용을 촉진하는 피부 미용 촉진제, 상기 피부 미용 촉진제를 배합하여 이루어지는 피부 미용을 촉진하기 위한 경구용 조성물, 및 피부 상태를 개선 및/또는 피부 미용을 촉진하기 위한 미용 방법을 제공하는 것을 과제로 하였다. 콜라겐 펩티드와 혈류 개선제 특히 동백나무 종자 추출물, 티옥트산류, 레스베라트롤류 및 레스베라트롤류를 함유하는 식물 추출물로 이루어지는 군으로부터 선택되는 1종 또는 2종 이상을 포함하여 이루어지는 병용물을 유효 성분으로서 포함하는 피부 미용 촉진제, 상기 피부 미용 촉진제를 배합하여 이루어지는 경구용 조성물, 또한 상기 피부 미용 촉진제 또는 상기 조성물을 경구 섭취하는 방법이 제공된다.The present invention provides a skin beauty accelerator for improving skin conditions such as drying of the skin, decreased elasticity, rough skin, and / or promoting skin beauty, an oral composition for promoting skin beauty by combining the skin beauty promoter, and An object of the present invention is to provide a cosmetic method for improving skin condition and / or promoting skin cosmetology. Skin comprising a combination comprising one or two or more selected from the group consisting of collagen peptides and blood flow improving agents, particularly plant extracts containing camellia seed extract, thioctic acid, resveratrol and resveratrol, as active ingredients An oral composition comprising a beauty accelerator, the skin beauty promoter, and a method for orally ingesting the skin beauty promoter or the composition are provided.
Description
본 발명은 콜라겐 펩티드와 혈류 개선제를 유효 성분으로서 함유하여 이루어지는 것을 특징으로 하는 피부의 주름, 습기, 땅김, 처짐 등의 피부 트러블을 개선하기 위한 및/또는 보다 아름다운 피부를 만들기 위한 피부 미용 촉진제, 상기 피부 미용 촉진제를 배합하여 이루어지는 경구용 조성물 및 이들의 이용 방법에 관한 것이다.The present invention comprises a collagen peptide and a blood flow improving agent as an active ingredient, wherein the skin beauty promoter for improving skin troubles such as wrinkles, moisture, wrinkles, sagging, and / or making more beautiful skin, The oral composition which mix | blends a skin beauty promoter, and its use method are related.
피부는 표피, 진피, 피하 조직으로 구성되어 있다. 표피는 각질층, 과립층, 유극층 및 기저층으로 구성되고, 케라티노사이트, 멜라노사이트 등의 세포를 많이 포함하고, 외계로부터 유해 물질이나 병원체의 침입을 방지하는 작용이나 수분의 증산을 억제하는 역할을 하고 있다. 진피에서는 표피와 달리 세포는 적고, 섬유아세포에 의해 생산된 콜라겐이나 엘라스틴 등의 단백질, 히알루론산이나 콘드로이틴 황산 등의 무코 다당류와 같은 세포외 성분으로 차 있고, 매트릭스 구조를 형성하여 세포 및 피부 조직의 지지, 세포 간극에 있어서의 수분 유지, 피부의 윤활성과 유연성의 유지, 자외선, 건조 환경, 기계적 자극이나 손상, 미생물 감염 등의 외적 인자로부터 피부 조직을 보호하는 등의 역할을 하고 있다(비특허문헌 1).The skin consists of the epidermis, dermis and subcutaneous tissue. The epidermis is composed of the stratum corneum, granule layer, polar layer and basal layer, and contains many cells such as keratinocytes and melanocytes, and acts to prevent invasion of harmful substances and pathogens from the outside world and to inhibit the evaporation of water. have. In the dermis, unlike the epidermis, the cells are small and are filled with extracellular components such as proteins such as collagen and elastin produced by fibroblasts, and mucopolysaccharides such as hyaluronic acid and chondroitin sulfate, and form matrix structures to form cells and skin tissues. It plays a role in protecting skin tissue from external factors such as support, maintenance of moisture in cell gaps, maintenance of lubricity and flexibility of skin, ultraviolet rays, dry environment, mechanical irritation and damage, and microbial infection. One).
그런데, 상기 세포외 매트릭스 성분은 가령이나 일상적인 자외선의 영향을 받아 변성·분해됨과 함께, 섬유아세포의 쇠약에 의해 그 합성량도 저하된다. 상기 세포외 매트릭스의 분해 및 합성량의 저하에 의해, 피부는 건조, 피부 거칠어짐, 탄력성이나 유연성의 저하, 땅김이나 광택의 감소, 주름, 처짐, 잡티의 증가 등의 여러 가지 피부 트러블을 일으키는 것이 알려져 있다. 따라서, 피부 상태의 개선 및/또는 피부 미용을 유지·증진하기 위해서는 피부의 세포를 활성화시키고, 가령이나 자외선에 의해 감소한 성분을 보충하고, 나아가 증강하는 것이 바람직하다고 여겨지고 있다. 특히 콜라겐은 피부 조직의 건조 중량당 약 70%를 차지하고, 피부의 점탄성에 깊이 관여하고 있다. 또한, 히알루론산은 피부 조직의 보습에 큰 영향을 미치고 있는 물질인 점에서, 피부 조직중의 콜라겐 및 히알루론산을 유지·증강하는 것이 중요하다.By the way, the extracellular matrix component is denatured and decomposed under the influence of, for example, ordinary ultraviolet rays, and the amount of its synthesis decreases due to the breakdown of fibroblasts. By decomposing and degrading the amount of the extracellular matrix, the skin causes various skin problems such as dryness, roughness of the skin, reduction of elasticity and flexibility, reduction of wrinkles and gloss, wrinkles, sagging, and blemishes. Known. Therefore, in order to improve skin condition and / or maintain and enhance skin beauty, it is considered that it is desirable to activate the cells of the skin, and to supplement and further enhance the components reduced by, for example, ultraviolet rays. Collagen in particular accounts for about 70% per dry weight of skin tissue and is deeply involved in the viscoelasticity of the skin. In addition, since hyaluronic acid is a substance having a great influence on the moisturization of skin tissue, it is important to maintain and enhance collagen and hyaluronic acid in the skin tissue.
콜라겐이나 히알루론산을 비롯한 피부 조직 중의 성분을 증강하거나 피부의 노화를 억제하기 위해서 여러 가지 성분이 종래부터 검토되고, 지금까지 젤라틴 및/또는 콜라겐의 분해물(특허문헌 1), N-아세틸글루코사민(특허문헌 2), 스핑고미엘린(특허문헌 3), 겐크와닌(특허문헌 4), 산딸기(특허문헌 5) 등이 제안되어 있다.In order to enhance components in skin tissues including collagen and hyaluronic acid or to inhibit aging of the skin, various components have been studied conventionally, and until now, a degradation product of gelatin and / or collagen (Patent Document 1) and N-acetylglucosamine (patent Document 2), sphingomyelin (patent document 3), genkwanin (patent document 4), wild strawberry (patent document 5), and the like have been proposed.
그러나, 이들 소재가 갖는 생리 작용을 생체내에서 발현시키기 위해서는, 다량으로 섭취할 필요가 있거나 장기간에 걸쳐 섭취하였다고 하더라도 개인에 따라서는 효과가 명확하지 않거나 일정한 효과밖에 얻지 못하는 경우도 있어 실용적으로 유효성을 발현할 수 있는 것은 얼마 안되었다. 따라서, 상기 피부 미용을 촉진하도록 하는 실효성이 있는 소재나 조성물의 개발이 요구되고 있었다.However, in order to express the physiological effects of these materials in vivo, even if ingested in a large amount or ingested for a long time, the effect is not clear or only a certain effect can be obtained depending on the individual. Very little can be expressed. Accordingly, there has been a demand for the development of effective materials and compositions for promoting the skin care.
그런데, 혈류 개선제란 생체의 각 조직에 혈액을 운반하는 기능을 개선하는 것이다. 혈액은 말초 조직에 대한 산소, 영양분, 수분, 호르몬 등의 공급, 면역 세포의 운반, 노폐물의 배출, 체온 조절 등을 행하고, 생체 조직의 기능 유지에 있어서 매우 중요한 역할을 담당하고 있다. 혈류을 개선함으로써 동맥경화증, 고혈압증, 면역력의 저하, 탈모증, 피로, 부종, 어깨 결림, 냉증, 손발의 무감각, 눈 밑의 기미나 피부의 잡티 등의 증상을 완화시키는 것이 알려져 있다.By the way, the blood flow improving agent is to improve the function of transporting blood to each tissue of the living body. The blood plays a very important role in supplying oxygen, nutrients, water, hormones, and the like to peripheral tissues, transporting immune cells, discharging waste products, controlling body temperature, and the like, and maintaining the function of biological tissues. By improving blood flow, it is known to alleviate symptoms such as atherosclerosis, hypertension, lowering of immunity, alopecia, fatigue, swelling, stiff shoulders, coldness, numbness of the hands and feet, blemishes under the eyes and skin blemishes.
혈류을 개선하는 물질로서는 예를 들어 은행나무 잎 엑기스, 잇꽃 추출물, 태반 엑기스, 고추 추출물, 캡사이신, 당근 엑기스, 쓴풀 엑기스, 후코이단, 비타민 E 및 그 유도체(아세트산토코페롤 등), 판토텐산 및 그 염(칼슘염, 나트륨염 등), 글리시리진산이나 글리시레틴산 및 그들의 염(나트륨염, 칼륨염 등), 타히보 엑기스, 아르기닌 및 그 유도체(아르기닌글루타메이트 등), 니코틴산 및 그 유도체(메틸에스테르 등), 로즈마리 추출물, 생강 엑기스, 생강올, 진저롤, 진저론, 이소플라본, 비타민 B3, 울금 추출물, 포도의 종자·잎·줄기 등의 추출물, 루틴, 쌀배아 발효 엑기스, 당귀 엑기스, 마늘 엑기스, 산초나무 엑기스 등이 제안되어 있다. 그러나, 이들 혈류 개선 물질과 상기 피부 노화 억제 성분의 조합이 피부 조직이나 피부 상태에 미치는 영향에 대하여 검토한 보고는 보이지 않는다.Examples of substances that improve blood flow include, for example, ginkgo leaf extract, safflower extract, placenta extract, pepper extract, capsaicin, carrot extract, bitter extract, fucoidan, vitamin E and its derivatives (such as tocopherol acetate), pantothenic acid and salts thereof (calcium salts). , Sodium salts, and the like), glycyrrhizinic acid and glycyrrhetinic acid and salts thereof (sodium salts, potassium salts, and the like), tahibo extract, arginine and its derivatives (arginine glutamate, etc.), nicotinic acid and its derivatives (such as methyl esters), and rosemary extract , Ginger extract, gingerol, ginger roll, ginger, isoflavone, vitamin B 3 , turmeric extract, extracts such as grape seeds, leaves and stems, rutin, rice germ fermentation extract, donkey extract, garlic extract, vinegar extract Is proposed. However, the report which examined the influence of the combination of these blood flow improving substances and the said skin antiaging component on skin tissue or a skin condition is not seen.
이러한 현황을 감안하여 본 발명자들은 피부의 건조, 탄력 저하, 피부 거칠어짐 등의 피부 상태의 개선 및/또는 피부 미용을 촉진하는 피부 미용 촉진제를 개발하고, 상기 피부 미용 촉진제를 배합하여 이루어지는 피부 미용을 촉진하기 위한 경구용 조성물, 및 피부 상태를 개선 및/또는 피부 미용을 촉진하기 위한 방법을 제공하는 것을 과제로 하였다.In view of the present situation, the present inventors have developed a skin beauty accelerator which improves skin conditions such as drying of the skin, decreased elasticity, roughness of the skin, and / or promotes skin beauty, and blends the skin beauty promoter An object of the present invention is to provide an oral composition for promoting and a method for improving skin condition and / or promoting skin cosmetology.
상기 과제를 해결하기 위해서 본 발명자들은 각종 다양한 소재와 피부 미용의 관련성에 대하여 예의 검토를 거듭한 결과, 콜라겐 펩티드와 혈류 개선 작용이 있는 것의 조합이 의외로 현저한 효과를 발휘하는 것, 혈류 개선 작용을 갖는 물질 중에서도 특히 동백나무 종자 추출물, 티옥트산류, 레스베라트롤류 및 레스베라트롤류를 함유하는 식물 추출물로부터 선택되는 적어도 1종을 콜라겐 펩티드와 병용하는 것이 매우 유효한 것을 발견하였다. 또한, 이것을 음식품, 사료, 의약품, 의약부외품 등의 경구 조성물에 유효하게 이용할 수 있는 것을 발견하고, 본 발명을 완성하기에 이르렀다.MEANS TO SOLVE THE PROBLEM In order to solve the said subject, the present inventors earnestly examined the relationship between various materials and skin beauty, and as a result, the combination of a collagen peptide and the thing which has a blood flow improving effect has an unexpectedly significant effect, and has a blood flow improving effect. Among the substances, it was found to be particularly effective to use at least one selected from plant extracts containing camellia seed extract, thioctic acid, resveratrol and resveratrol with collagen peptides. Moreover, it discovered that this can be used effectively for oral compositions, such as food-drinks, feedstuffs, medicines, and quasi-drugs, and came to complete this invention.
즉, 본 발명의 특징은 콜라겐 펩티드와 혈류 개선제를 유효 성분으로서 함유하여 이루어지는 피부 미용 촉진제에 있다. 이 피부 미용 촉진제에 있어서, 콜라겐 펩티드는 콜라겐, 젤라틴 및 이들의 가수분해물로 이루어지는 군에서 선택되는 1종 또는 2종 이상인 것이 바람직하고, 상기 가수분해물은 그 분자량(평균 분자량. 이하 마찬가지)이 약 200 내지 약 10,000인 것이 바람직하다. 또한, 혈류 개선제는 특히 동백나무 종자 추출물, 티옥트산류, 레스베라트롤류 및 레스베라트롤류를 함유하는 식물 추출물로 이루어지는 군에서 선택되는 1종 또는 2종 이상인 것이 바람직하다.That is, the feature of the present invention lies in a skin beauty accelerator comprising a collagen peptide and a blood flow improving agent as an active ingredient. In this skin care promoter, the collagen peptide is preferably one or two or more selected from the group consisting of collagen, gelatin and hydrolyzates thereof, and the hydrolyzate has a molecular weight (average molecular weight. Preferably from about 10,000. In addition, the blood flow improving agent is particularly preferably one or two or more selected from the group consisting of plant extracts containing Camellia seed extract, thioctic acid, resveratrol and resveratrol.
상기 동백나무 종자 추출물은 동백나무 종자의 탈지박(defatted meal)을 물 및/또는 저급 알코올로 추출 처리하여 얻어지는 수성 성분을 포함하는 것으로, 사포닌류를 포함하는 것이 바람직하고, 상기 사포닌류는 특히 카멜리아사포닌(Camelliasaponin) A1, 카멜리아사포닌 A2, 카멜리아사포닌 B1, 카멜리아사포닌 B2, 카멜리아사포닌 C1 및 카멜리아사포닌 C2 중에서 선택되는 1종 또는 2종 이상인 것이 보다 바람직하다.The camellia seed extract includes an aqueous component obtained by extracting and treating a defatted meal of camellia seed with water and / or a lower alcohol, and preferably includes saponins, and the saponins are particularly camellia. It is more preferable that it is 1 type, or 2 or more types chosen from a saponin A1, a camellia saponin A2, a camellia saponin B1, a camellia saponin B2, a camellia saponin C1, and a camellia saponin C2.
또한, 티옥트산류는 티옥트산(라세미체를 포함함), 그 환원체, 그들의 염, 그들의 에스테르, 그들의 아미드 및 그들의 시클로덱스트린 포접물 또는 지질 피복물로 이루어지는 군에서 선택되는 1종 또는 2종 이상의 것임이 바람직하다.In addition, the thioctic acid is one or two or more selected from the group consisting of thioctic acid (including racemates), its reduced bodies, their salts, their esters, their amides and their cyclodextrin inclusions or lipid coatings. Is preferred.
또한, 레스베라트롤류는 레스베라트롤의 단량체 또는 ε-비니페린 등의 중합체 및 이들의 이성체 및/또는 배당체로부터 이루어지는 군에서 선택되는 1종 또는 2종 이상을 포함하는 것임이 바람직하고, 그 형태는 포도과, 여뀌과 또는 콩과의 식물의 추출물이 보다 바람직하다.In addition, the resveratrol preferably contains one or two or more selected from the group consisting of monomers of resveratrol or polymers such as ε-viniferin, and isomers and / or glycosides thereof, and the form thereof is grape, Or the extract of the legume plant is more preferable.
본 발명의 다른 특징은 상기 피부 미용 촉진제를 경구적으로 섭취 또는 투여하는 것인 경구용 조성물이고, 이 경구용 조성물은 음식품인 것이 바람직하다. 또 다른 특징은 콜라겐 펩티드와 혈류 개선제를 경구 섭취하는 피부의 건조, 탄력 저하, 피부 거칠어짐 등의 피부 상태의 개선 및/또는 피부 미용을 촉진하기 위한 방법, 특히 미용 방법에 있다.Another feature of the present invention is an oral composition for orally ingesting or administering the skin beauty promoter, and the oral composition is preferably food or drink. Another feature is a method for promoting skin aesthetics and / or skin care, in particular a cosmetic method, such as drying, decreasing elasticity and roughening of the skin orally ingesting collagen peptides and blood flow improving agents.
본 발명의 피부 미용 촉진제는 콜라겐 펩티드와 혈류 개선제를 함유하여 이루어지고, 품질 등의 안정성이 우수하고, 피부 세포에 작용하여 그 증식을 현저하게 높이고, 콜라겐이나 히알루론산 등의 피부 성분의 생산을 촉진하고, 피부 조직 중의 성분을 회복·유지·증강한다. 혈류 개선제 중에서도 특히 동백나무 종자 추출물, 티옥트산류, 레스베라트롤류로부터 선택되는 적어도 1종류를 콜라겐 펩티드와 병용함으로써 이 작용이 증강된다. 이에 의해, 피부의 건조, 거칠함, 탄력성이나 유연성의 저하, 땅김이나 광택의 감소, 주름, 처짐, 잡티의 증가 등의 피부 트러블을 예방 및/또는 개선하고, 나아가서는 피부 미용을 촉진하는 효과를 발휘한다. 이러한 효과는 상기 피부 미용 촉진제를 경구적으로 섭취 또는 투여함으로써 현저하게 발현된다. 이로 인해, 상기 피부 미용 촉진제는 특히 음식품, 사료, 의약품, 의약부외품 등의 분야에 있어서, 상기 제의 형태인 채로 또는 종래의 각종 제품에 배합한 형태로 유효하게 이용할 수 있다. 또한, 본 발명에서는 콜라겐 펩티드와 혈류 개선제를 경구 섭취하는 피부의 건조, 탄력 저하, 피부 거칠어짐 등의 피부 상태를 개선 및/또는 피부 미용을 촉진하기 위한 미용 방법이 제공된다.The skin care promoter of the present invention contains a collagen peptide and a blood flow improving agent, and is excellent in stability such as quality, acts on skin cells to significantly increase its proliferation, and promotes the production of skin components such as collagen and hyaluronic acid. It restores, maintains, and enhances the components in skin tissue. Among the blood flow improving agents, this action is enhanced by using at least one kind selected from camellia seed extract, thioctic acid and resveratrol with collagen peptide. This prevents and / or improves skin troubles such as drying, roughness, deterioration of elasticity and flexibility, reduction of wrinkles and gloss, wrinkles, sagging, and blemishes, and further promoting skin beauty. Exert. This effect is markedly manifested by oral ingestion or administration of the skin care promoter. For this reason, the said skin beauty promoter can be used effectively in the form of said agent or mix | blended with various conventional products, especially in the field of food-drinks, feed, medicine, quasi drug, etc. In addition, the present invention provides a cosmetic method for improving skin conditions such as dryness, decreased elasticity, rough skin of the skin orally ingesting the collagen peptide and blood flow improving agent.
이하에 본 발명을 상세하게 설명한다. 우선, 본 발명의 피부 미용 촉진제는 콜라겐 펩티드와 혈류 개선제를 유효 성분으로서 함유하여 이루어지는 것을 특징으로 한다.Hereinafter, the present invention will be described in detail. First, the skin care promoter of the present invention is characterized by comprising a collagen peptide and a blood flow improving agent as an active ingredient.
본 발명의 피부 미용 촉진제에 이용하는 콜라겐 펩티드는 소, 돼지, 닭, 칠면조, 타조 등의 축류의 가죽, 뼈, 연골 또는 힘줄 등, 실꼬리돔, 연어, 상어, 대구, 틸라피아, 나일 퍼치, 잉어, 볼낙, 다랑어, 메기, 뱀장어 등의 어류의 가죽, 뼈, 연골 또는 비늘 등을 원료로 하여 통상법에 의해 처리하여 얻어지는 콜라겐 또는 당해 콜라겐을 열 변성시킨 젤라틴을 산, 알칼리 또는 효소로 가수분해한 펩티드이다. 여기서, 본 발명에 있어서의 콜라겐 펩티드란 콜라겐 펩티드 및 이것을 포함하는 추출물을 포함하고, 이들을 임의로 이용할 수 있다. 콜라겐 펩티드는 시판품을 이용하는 것이 간편하다.The collagen peptides used in the skin care promoter of the present invention are oxalic leathers, bones, cartilage or tendons, such as cattle, pigs, chickens, turkeys and ostrichs, thread-tail domes, salmon, sharks, cod, tilapia, nile perch, carp, It is a peptide obtained by hydrolyzing the skin of fish such as volnac, tuna, catfish, eel, etc. as a raw material, collagen obtained by a conventional method or gelatin obtained by heat-modifying the collagen with acid, alkali or enzyme. . Here, the collagen peptide in this invention contains a collagen peptide and the extract containing this, These can be used arbitrarily. The collagen peptide is easy to use a commercial item.
본 발명에 있어서는 콜라겐 또는 젤라틴을 가수분해한 콜라겐 펩티드를 이용하는 것이 바람직하고, 그 분자량은 약 200 내지 약 10,000의 것, 보다 바람직하게는 약 200 내지 약 5,000, 더욱 바람직하게는 약 200 내지 약 1,000의 것이다.In the present invention, it is preferable to use a collagen peptide obtained by hydrolyzing collagen or gelatin, and the molecular weight thereof is about 200 to about 10,000, more preferably about 200 to about 5,000, even more preferably about 200 to about 1,000 will be.
또한, 본 발명의 피부 미용 촉진제에 관한 혈류 개선제는 예를 들어 동백나무의 종자의 추출물, 티옥트산류, 레스베라트롤류, 레스베라트롤류를 함유하는 식물 추출물, 은행나무 잎 엑기스, 잇꽃 추출물, 태반 엑기스, 고추 추출물, 캡사이신, 당근 엑기스, 쓴풀 엑기스, 후코이단, 비타민 E 및 그 유도체(아세트산토코페롤 등), 판토텐산 및 그의 염(칼슘염, 나트륨염 등), 글리시리진산이나 글리시레틴산 및 그들의 염(나트륨염, 칼륨염 등), 타히보 엑기스, 아르기닌 및 그 유도체(아르기닌글루타메이트 등), 니코틴산 및 그 유도체(메틸에스테르 등), 로즈마리 추출물, 생강 엑기스, 생강올, 진저롤, 진저론, 이소플라본, 비타민 B3, 울금 추출물, 포도의 종자·잎·줄기 등의 추출물, 루틴, 쌀배아 발효 엑기스, 당귀 엑기스, 마늘 엑기스, 산초나무 엑기스 등을 사용할 수 있는데, 이들의 예시에 한정되지 않고 혈류 개선 작용이 있는 것의 1종 또는 2종 이상을 이용할 수 있다.In addition, the blood flow improving agent according to the skin care promoter of the present invention includes, for example, an extract of a camellia seed, a thioctic acid, a resveratrol, a plant extract containing resveratrol, a ginkgo leaf extract, a safflower extract, a placental extract, a red pepper Extracts, capsaicin, carrot extract, bitter extract, fucoidan, vitamin E and its derivatives (such as tocopherol acetate), pantothenic acid and salts thereof (calcium salts, sodium salts, etc.), glycyrrhizin or glycyrrhetinic acid and salts thereof (sodium salts, Potassium salts, etc.), tahibo extract, arginine and its derivatives (arginine glutamate, etc.), nicotinic acid and its derivatives (methyl esters, etc.), rosemary extract, ginger extract, gingerol, gingerol, ginger, isoflavones, vitamin B 3 , turmeric Extract, extracts such as grape seeds, leaves, and stems, rutin, rice germ fermentation extract, Angelica extract, garlic extract, and vinegar extract Although not limited to these examples, 1 type, or 2 or more types of those which have a blood flow improving effect can be used.
이와 관련하여 본 발명자들은 콜라겐 펩티드와 병용함으로써, 더한층 강력한 피부 미용 촉진 효과를 발휘할 수 있는 혈류 개선제를 더욱 상세하게 검토한 결과, 동백나무의 종자의 추출물, 티옥트산류 및 레스베라트롤류 또는 이것을 함유하는 식물 추출물이 매우 유효한 것을 발견하였다. 즉, 본 발명의 바람직한 피부 미용 촉진제는 전술한 콜라겐 펩티드와, 혈류 개선 작용이 있는 동백나무 종자 추출물, 티옥트산류, 레스베라트롤류 및 레스베라트롤류를 함유하는 식물 추출물로 이루어지는 군에서 선택되는 1종 또는 2종 이상을 유효 성분으로서 함유하여 이루어지는 것을 특징으로 하는 것이다.In this regard, the present inventors have studied blood flow improvers that can exert a more powerful skin beauty promoting effect by using in combination with collagen peptides, and as a result, extracts of the camellia seeds, thioctal acids and resveratrol or plants containing them The extract was found to be very effective. That is, the preferred skin care promoter of the present invention is one or two selected from the group consisting of the above-described collagen peptide and a plant extract containing a camellia seed extract, thioctic acid, resveratrol and resveratrol having a blood flow improving action. It is characterized by containing more than 1 type as an active ingredient.
본 발명에 따른 동백나무 종자 추출물에 대하여 이하에 상세하게 설명한다. 동백나무는 동백나무과(Theaceae) 동백나무속(Camellia)의 동백나무절에 속하는 동백나무(Camellia japonica)를 말하고, 그 예로서 야생동백나무(C. japonica var. japonica), 유키동백나무(C. japonica subsp. rusticana), 사과동백나무(C. japonica var. macrocarpa), 호잔동백나무(C. japonica subsp. hozanensis), 홍콩동백나무(C. hongkongenesis), 토우동백나무(C. reticulata), 살윈동백나무(C. saluenensis), 피탈동백나무의 피탈디종(C. pitardii var. pitardii) 및 윈난종 (C. pitardii var. yunnanica), 금화차(C. nitidissima), 산동백나무(야생동백나무와 동종), 산다화(야생동백나무와 동종), 야쿠시마동백나무(사과동백나무와 동종) 등을 들 수 있다. 이들 동백나무는 일본 열도, 한반도, 중국 산동 반도 등에서 자생하거나 또는 재배되고 있는 것을 적절하게 이용하면 된다.Camellia seed extract according to the present invention will be described in detail below. Camellia refers to Camellia japonica, which belongs to the Camellia section of Theaceae Camellia, and includes, for example, wild camellias (C. japonica var. Japonica) and Yuki camellia (C. japonica). subsp. rusticana, C. japonica var. macrocarpa, C. japonica subsp. hozanensis, C. hongkongenesis, C. reticulata, Salmon camellia (C. saluenensis), C. pitardii var. Pitardii and Yunnan species (C. pitardii var. Yunnanica), C. nitidissima, Shandong camellia (same as wild camellia) , Wild flowers (same as wild camellia) and Yakushima camellia (same as apple camellia). These camellia trees may be grown or grown on the Japanese archipelago, the Korean peninsula, and Shandong peninsula, China.
본 발명에 따른 동백나무 종자 추출물을 제조하기 위해서는 상기한 동백나무의 열매 및/또는 종자를 압착 처리, 헥산이나 헵탄 등의 소수성 유기 용매 또는 액화 이산화탄소, 액화 프로판 등의 액화 가스를 이용한 초임계 추출 처리 등에 제공하여 통상법에 의해 유분을 추출하여 분리한 잔사인 탈지물(이하, 탈지박이라고 하는 경우가 있음)을 원료로 하는 것이 바람직하다. 여기서, 동백나무의 열매 및/또는 종자는 조숙 열매 및 성숙 열매의 어느 것이어도 되며, 이들의 종자를 이용하여도 되지만, 성숙 열매 또는 그 종자를 이용하면 탈지물 또는/및 유효 성분의 수량이 많아져서 바람직하다. 보다 바람직하게는 종자를 이용한다. 바람직한 형태로서 성숙 열매로부터 얻어지는 종자를 1 내지 2주일 정도 햇볕 등에서 건조시킨 것을 이용한다.In order to prepare the Camellia seed extract according to the present invention, the fruit and / or seeds of the Camellia japonica are compressed, and a supercritical extraction treatment using a hydrophobic organic solvent such as hexane or heptane or a liquefied gas such as liquefied carbon dioxide or liquefied propane. It is preferable to use, as a raw material, a degreasing material (hereinafter sometimes referred to as a degreasing foil) which is a residue obtained by providing an oil or the like and extracting an oil component by a conventional method. Here, the fruits and / or seeds of the camellia may be any of ripe and mature fruits, and may be used as their seeds. However, when the mature fruits or the seeds are used, the amount of skim or / and the active ingredient is large. It is preferable to lose. More preferably, seeds are used. As a preferable form, what dried the seed obtained from mature fruit in sunlight etc. for about 1 to 2 weeks is used.
본 발명에 따른 동백나무 종자 추출물의 활성 성분은 바람직하게는 수성 성분이다. 이 수성 성분은 상기 탈지박을 원료로 하여 임의의 방법으로 제조하는 것이 가능한데, 물 및/또는 저급 알코올을 이용하여 추출 처리하는 것이 바람직하다. 저급 알코올은 그 탄소수가 커지면 탈지박 중의 유성 물질이 추출되는 경향이 커지기 때문에, 탄소수가 5 정도까지의 것이 바람직하고, 메탄올, 에탄올, 노르말프로판올, 이소프로판올, 노르말부탄올, 이소부탄올 등을 예시할 수 있다. 탄소수가 큰 저급 알코올을 사용하는 경우에는, 탈지박 중의 유성 성분의 추출을 억제하기 위해서 함수율을 높이는 것이 좋다. 예를 들어 프로판올의 경우의 함수율은 약 20 내지 약 50질량%로 하고, 부탄올의 경우의 함수율은 약 40 내지 약 70질량%로 한다. 바람직한 추출 용매는 물, 메탄올 및 에탄올 및 이들의 함수 알코올이고, 보다 바람직하게는 물 또는 함수율이 50질량% 이상인 함수 메탄올 또는 함수 에탄올이고, 더욱 바람직하게는 물이다.The active ingredient of the Camellia seed extract according to the present invention is preferably an aqueous ingredient. Although this aqueous component can be manufactured by arbitrary methods using the said skim foil as a raw material, it is preferable to extract-process using water and / or a lower alcohol. Since the lower alcohol has a tendency to extract oily substance in skim foil as the carbon number becomes large, it is preferable that carbon number is up to about 5, and methanol, ethanol, normal propanol, isopropanol, normal butanol, isobutanol, etc. can be illustrated. . When using a lower alcohol having a large carbon number, it is preferable to increase the water content in order to suppress extraction of the oily component in the skim foil. For example, the water content in the case of propanol is about 20 to about 50 mass%, and the water content in the case of butanol is about 40 to about 70 mass%. Preferred extraction solvents are water, methanol and ethanol and their hydrous alcohols, more preferably water or hydrous methanol or hydrous ethanol having a water content of 50% by mass or more, still more preferably water.
탈지박을 추출하기 위해서는 탈지박 1질량부에 대하여 상기 추출 용매를 약 1 내지 약 30 질량배 첨가하고, 상압하 또는 약 1 내지 약 5기압의 가압하, 상온 내지 약 120℃에서 약 10분 내지 약 3시간, 필요에 따라 교반하여 혼합 후, 상온에 냉각하여 여과하고, 여과액을 감압 건조, 분무 건조, 동결 건조 등의 적당한 수단에 의해 농축, 건조한다. 이 건조물은 적절하게 분쇄 처리하여도 된다. 이와 같이 하여 본 발명에 따른 동백나무 종자에 포함되는 수용성 성분인 담황색 또는 황적색의 고체를 얻을 수 있다. 상기 추출 방법은 일단 추출 처리한 추출 잔사를 마찬가지로 반복 추출 처리하거나 약 1 내지 약 3기압의 가압하 약 100 내지 약 130℃에서 행함으로써, 본 발명에 따른 수용성 성분의 수량을 증가시키는 것도 가능하고, 또한 상기 추출물을 또한 용제 분별, 이온 교환 수지, 실리카 겔, 활성 알루미나 등의 흡착제를 충전한 칼럼에 의한 분획, 액체 크로마토그래피에 의한 분취 등의 공지된 수단에 제공하여 활성 성분을 농축, 정제할 수도 있다. 이 수용성 성분은 사포닌, 탄닌 등을 포함한다.In order to extract skim foil, about 1 to about 30 mass times of the said extraction solvent is added with respect to 1 mass part of skim foil, and it is about 10 minutes at normal temperature-about 120 degreeC under normal pressure or about 1 to about 5 atmospheres of pressurization. After stirring and mixing for about 3 hours if necessary, the mixture is cooled to room temperature and filtered, and the filtrate is concentrated and dried by suitable means such as drying under reduced pressure, spray drying, and freeze drying. You may grind this dried material suitably. In this way, a pale yellow or yellow red solid, which is a water-soluble component contained in the camellia seed according to the present invention, can be obtained. The extraction method is also possible to increase the amount of water-soluble components according to the present invention by carrying out the extraction residue once subjected to the extraction extraction in the same manner or by repeating the extraction at about 100 to about 130 ℃ under pressure of about 1 to about 3 atmospheres, The extract may also be provided to known means, such as fractionation by a column filled with adsorbents such as solvent fractionation, ion exchange resins, silica gel, activated alumina, and fractionation by liquid chromatography, to concentrate and purify the active ingredient. have. This water-soluble component includes saponins, tannins, and the like.
상기 수용성 성분에 포함되는 사포닌으로서 3β-[2-O-β-D-갈락토피라노실-3-O-(2-O-β-D-글루코피라노실-α-L-아라비노피라노실)-β-D-글루코피라누로노실옥시]올레아나-12-엔-16α,22α,28-트리올22-[(Z)-2-메틸-2-부테노에이트]인 카멜리아사포닌(Camelliasaponin) A1, 3β-[2-O-β-D-갈락토피라노실-3-O-(2-O-β-D-글루코피라노실-α-L-아라비노피라노실)-β-D-글루코피라누로노실옥시)올레아나-12-엔-16α,22α,28-트리올22-[(E)-2-메틸-2-부테노에이트]인 카멜리아사포닌(Camelliasaponin) A2, 3β-[2-O-β-D-갈락토피라노실-3-O-(2-O-β-D-글루코피라노실-α-L-아라비노피라노실)-β-D-글루코피라누로노실옥시)-16α,28-디히드록시-22α-[[(Z)-2-메틸-2-부테노일]옥시]올레아나-12-엔-23-알인 카멜리아사포닌(Camelliasaponin) B1, 3β-[[2-O-β-D-갈락토피라노실-3-O-(2-O-β-D-글루코피라노실-α-L-아라비노피라노실)-β-D-글루코피라누로노실)옥시]-16α,28-디히드록시-22α-[[(E)-2-메틸-2-부테노일]옥시]올레아나-12-엔-23-알인 카멜리아사포닌(Camelliasaponin) B2, 3β-[2-O-β-D-갈락토피라노실-3-O-(2-O-β-D-글루코피라노실-α-L-아라비노피라노실)-β-D-글루코피라누로노실옥시]올레아나-12-엔-16α,22α,23,28-테트라올22-[(Z)-2-메틸-2-부테노에이트]인 카멜리아사포닌(Camelliasaponin) C1 및 3β-[2-O-β-D-갈락토피라노실-3-O-(2-O-β-D-글루코피라노실-α-L-아라비노피라노실)-β-D-글루코피라누로노실옥시]올레아나-12-엔-16α,22α,23,28-테트라올22-[(E)-2-메틸-2-부테노에이트]인 카멜리아사포닌(Camelliasaponin) C2 등을 예시할 수 있다. 이들 사포닌류는 동백나무에 특이적으로 포함되어 있다.3β- [2-O-β-D-galactopyranosyl-3-O- (2-O-β-D-glucopyranosyl-α-L-arabinofyranosyl) included as the saponin contained in the water-soluble component. Camelliasaponin A1 which is -β-D-glucopyranuronosyloxy] oleana-12-ene-16α, 22α, 28-triol22-[(Z) -2-methyl-2-butenoate] , 3β- [2-O-β-D-galactopyranosyl-3-O- (2-O-β-D-glucopyranosyl-α-L-arabinopyranosyl) -β-D-glucopyra Camelliasaponin A2, 3β- [2-O, which is noronosyloxy) oleana-12-ene-16α, 22α, 28-triol22-[(E) -2-methyl-2-butenoate] -β-D-galactopyranosyl-3-O- (2-O-β-D-glucopyranosyl-α-L-arabinopyranosyl) -β-D-glucopyranuronosyloxy) -16α, Camelliasaponin B1, 3β-[[2-O-, 28-dihydroxy-22α-[[(Z) -2-methyl-2-butenyl] oxy] oleana-12-ene-23-al β-D-galactopyranosyl-3-O- (2-O-β-D-glucopyranosyl-α-L-arabinofyranosyl) -β-D-glucopy Ranulinosyl) oxy] -16α, 28-dihydroxy-22α-[[((E) -2-methyl-2-butenyl] oxy] oleana-12-ene-23-al, Camelliasaponin B2 , 3β- [2-O-β-D-galactopyranosyl-3-O- (2-O-β-D-glucopyranosyl-α-L-arabinopyranosyl) -β-D-glucopyra Camelliasaponin C1 and 3β- [2 which are noronosyloxy] oleana-12-ene-16α, 22α, 23,28-tetraol22-[(Z) -2-methyl-2-butenoate] -O-β-D-galactopyranosyl-3-O- (2-O-β-D-glucopyranosyl-α-L-arabinopyranosyl) -β-D-glucopyranuronosyloxy] ole Camelliasaponin C2 which is anana-12-ene-16α, 22α, 23,28-tetraol22-[(E) -2-methyl-2-butenoate], etc. can be illustrated. These saponins are specifically contained in Camellia.
또한, 본 발명에 따른 티옥트산류는 그 기원이나 종류는 특별히 한정되는 것은 아니며, 소나 돼지의 간장 등 장기의 천연물 추출물이나, 예를 들어 에틸렌 및 아디프산에스테르를 출발 원료로 하는 화학적 합성품 등 공지된 방법으로 채취, 제조된 것이어도 된다. 또한, 티옥트산은 비대칭 탄소를 갖기 때문에 광학적 성질이 상이한 거울상 이성체((R)-에난티오머 및 (S)-에난티오머)가 존재하는데, 본 발명에 따른 티옥트산은 이들 중 어느 단독이어도 임의 비율의 혼합물이어도 되며, 또한 라세미체(라세미 혼합물이나 라세미 화합물)((R),(S)-티옥트산)이어도 지장없다. 공업 생산 레벨의 실시에 있어서는 저렴하고 용이하게 입수할 수 있는 시판되는 라세미체를 이용하는 것이 간편하다. 라세미체를 이용하면 본 발명의 원하는 효과를 보다 강력하게 발현하는 경향이 크므로 바람직하다.In addition, the origin and type of the thioctic acid according to the present invention are not particularly limited, and it is well known such as extracts of natural products of organs such as soy sauce of cows and pigs, and chemical synthetic products using, for example, ethylene and adipic acid as starting materials. It may be collected and manufactured by the conventional method. In addition, since thioctic acid has an asymmetric carbon, enantiomers ((R) -enantiomer and (S) -enantiomer) having different optical properties exist, and the thioctic acid according to the present invention may be any of these alone. The mixture of ratios may be sufficient, and a racemate (racemic mixture and a racemic compound) ((R), (S)-thioctic acid) may be sufficient. In carrying out the industrial production level, it is easy to use a commercially available racemate which is inexpensive and easily available. Use of the racemate is preferable because it tends to express more strongly the desired effect of the present invention.
본 발명의 피부 미용 촉진제에 사용하는 티옥트산류는 상기한 티옥트산 외에 각종 유도체를 적절하게 이용할 수 있고, 티옥트산, 그 환원체, 그들의 염, 그들의 에스테르, 그들의 아미드 및 그들의 시클로덱스트린 포접물로 이루어지는 군에서 선택되는 1종 또는 2종 이상의 것임이 바람직하다.The thioctic acid used for the skin care promoter of the present invention can be suitably used in addition to the above-described thioctic acid, and is composed of thioctic acid, its reducing agent, their salts, their esters, their amides and their cyclodextrin inclusions. It is preferable that it is 1 type, or 2 or more types selected from the group.
티옥트산의 환원체의 구체예로서는 디히드로티옥트산, 디히드로리포산, 6,8-디머캅토-옥탄산, (R),(S)-디히드로티옥트산 등을 들 수 있다.As a specific example of the reducing agent of thioctic acid, dihydrothioctic acid, dihydrolipoic acid, 6,8- dimercapto-octanoic acid, (R), (S) -dihydrothioctic acid, etc. are mentioned.
염으로서는 (R)-티옥트산, (S)-티옥트산, (R),(S)-티옥트산, (R)-디히드로티옥트산, (S)-디히드로티옥트산, (R),(S)-디히드로티옥트산 등의 칼륨염, 나트륨염, 칼슘염, 마그네슘염 등을 들 수 있다.As a salt, it is (R)-thioctic acid, (S)-thioctic acid, (R), (S)-thioctic acid, (R)-dihydrothioctic acid, (S)-dihydrothioctic acid, (R), ( Potassium salts, such as S) -dihydrothioctic acid, a sodium salt, a calcium salt, a magnesium salt, etc. are mentioned.
에스테르로서는 (R)-티옥트산, (S)-티옥트산, (R),(S)-티옥트산, (R)-디히드로티옥트산, (S)-디히드로티옥트산, (R),(S)-디히드로티옥트산 등과 다가 알코올(에틸렌글리콜, 프로필렌글리콜, 부탄디올, 네오펜틸글리콜, 글리세린, 에리트리톨, 폴리글리세린 등의 단량체 또는 중합체)과의 부분 에스테르 또는 완전 에스테르 또는 글리세라이드류(모노글리세라이드, 디글리세라이드, 트리글리세라이드), 또는 탄소수 10 내지 22의 고급 알코올류(데칸올, 라우릴알코올, 미리스틸알코올, 세탄올, 스테아릴알코올, 이소스테아릴알코올, 베헤닐알코올 등)와의 모노에스테르 등을 들 수 있다.Examples of the ester include (R) -thioctic acid, (S) -thioctic acid, (R), (S) -thioctic acid, (R) -dihydrothioctic acid, (S) -dihydrothiocic acid, (R), ( S)-partial esters or complete esters or glycerides (monoglycers) with dihydrothioctic acid and polyhydric alcohols (monomers or polymers such as ethylene glycol, propylene glycol, butanediol, neopentyl glycol, glycerin, erythritol, polyglycerol) Lides, diglycerides, triglycerides) or mono alcohols having 10 to 22 carbon atoms (decanol, lauryl alcohol, myristyl alcohol, cetanol, stearyl alcohol, isostearyl alcohol, behenyl alcohol, etc.) Ester etc. are mentioned.
아미드로서는 (R)-티옥트산, (S)-티옥트산, (R),(S)-티옥트산, (R)-디히드로티옥트산, (S)-디히드로티옥트산, (R),(S)-디히드로티옥트산 등의 아미드를 예시할 수 있다.Examples of the amides include (R) -thioctic acid, (S) -thioctic acid, (R), (S) -thioctic acid, (R) -dihydrothioctic acid, (S) -dihydrothioctic acid, (R), ( Amides, such as S) -dihydrothioctic acid, can be illustrated.
시클로덱스트린 포접물로서는 α-, β-, γ- 또는 δ-시클로덱스트린과 상기 티옥트산 또는 그 유도체의 포접물을 예시할 수 있다.Examples of cyclodextrin inclusions include inclusions of α-, β-, γ-, or δ-cyclodextrin and the thioctic acid or derivatives thereof.
또한, 본 발명은 이들 예시에 의해 한정되는 것은 아니다.In addition, this invention is not limited by these illustrations.
본 발명에서는 티옥트산류로서 상기한 티옥트산, 그 환원체, 그들의 염, 그들의 에스테르, 그들의 아미드 및 그들의 시클로덱스트린 포접물로 이루어지는 군에서 선택되는 1종 또는 2종 이상의 결정, 분말 및/또는 입자의 외표면을 지질류로 피복하여 이루어지는 것도 포함하고, 이 형태는 티옥트산류의 열적 변질(분해, 중합, 변색 등), 흡습 또는 산화적 변성을 억제하기 위해서 실용적으로는 한층 바람직한 것이다.In the present invention, one or two or more crystals, powders and / or particles selected from the group consisting of the above-described thioctic acid, its reducing agent, their salts, their esters, their amides and their cyclodextrin inclusions as thioctal acids The outer surface is covered with lipids, and this form is more practically preferable in order to suppress thermal deterioration (decomposition, polymerization, discoloration, etc.), moisture absorption, or oxidative degeneration of thioctic acids.
상기 티옥트산류의 결정, 분말 및/또는 입자의 외표면을 피복하는 지질류는, 본 발명이 이용되는 산업 분야에 있어서 허용되는 것이면 되며, 일반의 식용유 지방류 또는 공업용 유지류, 지방산 글리세라이드류, 지방산류, 지방산 에스테르류, 지방산 아미드류, 고급 알코올류, 왁스류, 스테롤류, 당지질류, 인지질류 등을 단독으로 또는 조합하여 이용할 수 있다. 이들 중 피복 작업성 및 피복물의 물성(안정성, 고화성, 유동성, 용융성, 용해성 등)을 고려하면, 융점이 약 30℃ 이상인 지질류가 좋다. 보다 바람직한 형태는 융점이 약 40℃ 내지 약 70℃인 지질류이고, 더욱 바람직한 형태는 융점이 약 40℃ 내지 약 60℃인 지질류이다. 융점이 약 30℃를 하회하면, 피복물이 그 사용시에 고형 상태를 유지할 수 없는 경우가 있고, 괴상물을 형성하는 경우가 있거나 또는 유동성을 손상시키는 경우가 있다. 반대로 약 70℃를 상회하면, 본 발명에 따른 조해제나 조성물을 제조할 때의 가열 처리나 기계적 에너지의 영향으로 티옥트산류 자체가 열화될 우려가 있다.Lipids which coat the outer surface of the crystals, powders and / or particles of the thioctic acid may be acceptable in the industrial field in which the present invention is used, and common edible oil fats or industrial fats and oils, fatty acid glycerides and fatty acids , Fatty acid esters, fatty acid amides, higher alcohols, waxes, sterols, glycolipids, phospholipids and the like can be used alone or in combination. In consideration of coating workability and physical properties (stability, solidification, flowability, meltability, solubility, etc.) of these, lipids having a melting point of about 30 ° C. or more are preferable. More preferred forms are lipids having a melting point of about 40 ° C. to about 70 ° C., and still more preferred forms are lipids having a melting point of about 40 ° C. to about 60 ° C. When melting | fusing point is less than about 30 degreeC, a coating may not be able to maintain a solid state at the time of its use, may form a mass, or may impair fluidity. On the contrary, when it exceeds about 70 degreeC, there exists a possibility that the thioctic acid itself may deteriorate under the influence of heat processing and mechanical energy at the time of manufacturing a deliquescent agent or a composition which concerns on this invention.
이러한 지질류의 구체예로서 대두유, 채종유, 콘유, 해바라기 오일, 면실유, 소맥 배아유, 미유, 참기름, 올리브유, 홍화유, 팜유, 팜핵유, 야자유, 아마인유, 낙화생유 등의 식물계 유지, 우지, 라드, 어유 등의 동물계 유지, 이들에 분별, 에스테르 교환, 탈색, 탈취 등의 처리 중 1개 이상을 실시한 가공 유지, 이들을 부분적 또는 완전히 수소 첨가 처리한 각종 경화유, 탄소수 2 내지 22의 포화 지방산(아세트산, 부티르산, 카프로산, 카프릴산, 카프르산, 라우르산, 미리스트산, 펜타데칸산, 팔미트산, 스테아르산, 12-히드록시스테아르산, 이소스테아르산, 아라키드산, 베헨산 등) 또는 불포화 지방산(팔미톨레산, 올레산, 엘라이드산, 리놀산, α-리놀렌산, γ-리놀렌산, 리시놀산, 아라키돈산, 이코사펜타에노산(EPA), 에루크산, 도코사헥사엔산(DHA) 등), 이들의 임의의 지방산의 염류(나트륨염, 칼륨염, 칼슘염, 마그네슘염 등), 1가 알코올(메탄올, 에탄올, 프로판올, 부탄올 등)과의 에스테르류, 다가 알코올(에틸렌글리콜, 프로필렌글리콜, 부탄디올, 네오펜틸글리콜, 글리세린, 에리트리톨 등의 단량체 또는 중합체)과의 부분 또는 완전 에스테르류, 또는 글리세라이드류(모노글리세라이드, 디글리세라이드, 트리글리세라이드), 탄소수 10 내지 22의 고급 알코올류(데칸올, 라우릴알코올, 미리스틸알코올, 세탄올, 스테아릴알코올, 이소스테아릴알코올, 베헤닐알코올 등), 왁스류(카르나우바 왁스, 라이스 왁스(쌀겨납), 칸델릴라 왁스 등의 식물 유래 왁스, 밀랍, 경랍, 셸락 왁스 등의 동물 유래 왁스, 파라핀 왁스, 마이크로크리스탈린 왁스 등의 석유 유래 왁스, 몬탄 왁스, 오조케라이트 등의 광물 유래 왁스, 폴리에틸렌 왁스, 상기 지방산류와 상기 고급 알코올류의 에스테르 등의 합성 왁스), 스테롤류(동물성 콜레스테롤, 식물성 캄페스테롤, 스티그마스테롤, 시토스테롤 등, 균류 유래의 에르고스테롤, 이들의 유도체), 인지질류(동식물 유래의 레시틴, 포스파티딜콜린, 포스파티딜에탄올아민, 포스파티딜이노시톨, 포스파티딜세린, 포스파티딘산, 스핑고미엘린 등), 당지질류(모노글루코실디글리세라이드, 모노갈락토실디글리세라이드, 디글루코실모노글리세라이드, 디갈락토실모노글리세라이드, 모노글루코실디글리세라이드, 디갈락토실디글리세라이드, 자당 지방산 에스테르 등)를 들 수 있다. 또한, 본 발명은 이들 예시에 의해 전혀 한정되는 것은 아니다.Specific examples of such lipids include vegetable oils such as soybean oil, rapeseed oil, corn oil, sunflower oil, cottonseed oil, wheat germ oil, brown oil, sesame oil, olive oil, safflower oil, palm oil, palm kernel oil, palm oil, linseed oil, peanut oil, tallow, lard. Animal fats and oils such as fish oil, processed fats and oils subjected to one or more of such treatment as fractionation, transesterification, decolorization, deodorization, various hydrogenated oils partially or completely hydrogenated, saturated fatty acids having 2 to 22 carbon atoms (acetic acid, Butyric acid, caproic acid, caprylic acid, capric acid, lauric acid, myristic acid, pentadecanoic acid, palmitic acid, stearic acid, 12-hydroxystearic acid, isostearic acid, arachidic acid, behenic acid, etc. ) Or unsaturated fatty acids (palmitoleic acid, oleic acid, elideic acid, linoleic acid, α-linolenic acid, γ-linolenic acid, ricinolic acid, arachidonic acid, icosapentaenoic acid (EPA), erucic acid, docosahexaenoic acid ( DHA), etc.), Salts of fatty acids (sodium salt, potassium salt, calcium salt, magnesium salt, etc.), esters with monohydric alcohols (methanol, ethanol, propanol, butanol, etc.), polyhydric alcohols (ethylene glycol, propylene glycol, butanediol, neopentyl Partial or complete esters with monomers or polymers such as glycol, glycerin, erythritol, or glycerides (monoglycerides, diglycerides, triglycerides), higher alcohols having 10 to 22 carbon atoms (decanol, la) Plant-derived waxes such as uril alcohol, myristyl alcohol, cetanol, stearyl alcohol, isostearyl alcohol, behenyl alcohol, etc., waxes (carnauba wax, rice wax (rice bran), candelilla wax, etc. Animal-derived waxes such as sperm, shellac wax, petroleum-derived waxes such as paraffin wax, microcrystalline wax, mineral-derived waxes such as montan wax, ozokerite, poly Styrene wax, synthetic waxes such as esters of the fatty acids and higher alcohols), sterols (eg, animal cholesterol, phytocamphor, stigmasterol, cytosterol, ergosterol derived from fungi, derivatives thereof), phospholipids (animals and animals) Derived lecithin, phosphatidylcholine, phosphatidylethanolamine, phosphatidyl inositol, phosphatidylserine, phosphatidic acid, sphingomyelin, and the like Lactosyl monoglycerides, monoglucosyl diglycerides, digalactosyl diglycerides, sucrose fatty acid esters, and the like. In addition, this invention is not limited at all by these illustrations.
본 발명에서는 상기 각종 지질류 중 어느 1종 또는 2종 이상의 혼합물을 사용할 수 있지만, 바람직한 지질류의 종류는 상기한 식용유 지방류 또는 공업용 유지류, 지방산 글리세라이드류, 지방산 에스테르류 및 왁스류이고, 보다 바람직하게는 식용유 지방류 및 지방산 글리세라이드류이고, 또한 이들과 지방산류, 고급 알코올류, 스테롤류, 당지질류 또는 인지질류로부터 선택되는 1종 또는 2종 이상의 조합은 피복 지질의 융점 조정, 피복막 강화 등의 점으로부터 더욱 바람직한 형태이다.In the present invention, any one kind or a mixture of two or more kinds of the above-mentioned various lipids can be used, but the preferred kinds of lipids are the above-mentioned cooking oil fats or industrial fats and oils, fatty acid glycerides, fatty acid esters and waxes, and more preferably. Preferably, they are cooking oil fats and fatty acid glycerides, and one or two or more combinations thereof selected from fatty acids, higher alcohols, sterols, glycolipids, or phospholipids may be used to adjust melting point of coating lipids, strengthen membrane coating, and the like. It is a more preferable form from the point of.
티옥트산류의 결정, 분말 및/또는 입자의 외표면을 지질류로 피막하기 위해서는 공지된 방법을 이용할 수 있다. 즉, 볼 밀, 플래시 블렌더(분립체 혼합기), V형 혼합기, 고속 믹서, 고속 패들 믹서, 가열 용융 혼합기, 초음파 과습 가액형 혼합기, 텀블러 혼합기, 가압 압출기 등을 이용하여, 티옥트산류의 결정, 분말 및/또는 입자와 가열 용융한 지질류를 균일하게 혼합하고, 냉각하여 고화시킨 후 이것을 분쇄하는 방법, 상기 형태의 티옥트산류에 적절히 가열하여 액상화한 지질류를 분무 또는 적하하여 피복하는 방법, 상기 형태의 티옥트산류와 입자상의 지질류를 고속 교반하여 혼합하고, 양자를 접촉 또는 충돌시킴으로써 티옥트산류의 결정, 분말 및/또는 입자의 표면 전체에 입자상의 지질류를 균일하게 부착시켜 피복하는 방법 등이 가능하다. 본 발명에서는 이들 중 티옥트산류의 결정, 분말 및/또는 입자와 전술한 특정 융점 이상의 입자상 지질류를 고속 교반하여 혼합하고, 양자를 접촉 또는 충돌시켜 상기 형태의 티옥트산류의 표면 전체에 입자상의 지질류를 균일하게 피복시키는 방법이 바람직하다.Known methods can be used to coat the outer surface of crystals, powders and / or particles of thioctic acids with lipids. Namely, crystallization of thioctic acid using a ball mill, a flash blender (powder mixer), a V-type mixer, a high speed mixer, a high speed paddle mixer, a hot melt mixer, an ultrasonic humidifying liquid mixer, a tumbler mixer, a pressure extruder, and the like, A method of uniformly mixing powders and / or particles with heat-melted lipids, cooling and solidifying them, and then pulverizing them, spraying or dropping the liquid-liquefied lipids by appropriately heating the above-described form of thioctic acid, A mixture of thioctic acid and particulate lipids of the above form by high-speed agitation and contacting or colliding the same to uniformly attach and coat particulate lipids over the entire surface of crystals, powders and / or particles of the thioctic acid. Method and the like are possible. In the present invention, among these, crystals, powders and / or particles of thioctic acids and particulate lipids having a specific melting point or higher mentioned above are mixed and mixed at high speed, and both of them are contacted or collided to form particulates on the entire surface of the thioctic acid of the above-described type. It is preferable to coat the lipids uniformly.
전술한 피복 처리시에 티옥트산류의 결정, 분말 및/또는 입자와 지질류의 비율은, 티옥트산류의 결정, 분말 및 입자의 형상이나 크기, 지질류의 종류 및 융점, 피복막의 두께와 성상 등의 요인에 의해 일률적으로 규정하기는 어렵지만, 대강 티옥트산류의 결정, 분말 및/또는 입자 1질량부에 대하여 지질류 약 0.05 내지 약 10질량부, 바람직하게는 약 0.1 내지 약 5질량부이다. 지질류가 약 0.05질량부 미만이면 피복 상태가 충분하지 않아 원하는 효과를 발현하기 어려워지고, 반대로 약 10질량부를 초과하면 피복물 중의 티옥트산 함량이 적고, 피복물을 이용하는 경우에 있어서 배합율 등이 제한되어 실용적 가치를 손상시키는 경우가 있다.In the coating treatment described above, the ratio of crystals, powders and / or particles to lipids of the thioctic acid is determined by the crystals, the shape and size of the powders and particles, the type and melting point of the lipids, and the thickness and properties of the coating film. Although it is difficult to define uniformly by such factors, it is about 0.05 to about 10 parts by mass of lipids, preferably about 0.1 to about 5 parts by mass, based on 1 part by mass of crystals, powders and / or particles of roughly thioctic acids. . If the lipids are less than about 0.05 parts by mass, the coating state is insufficient, making it difficult to express a desired effect. On the contrary, if the amount of the lipids exceeds about 10 parts by mass, the content of the titanic acid in the coating is low, and when the coating is used, the blending ratio is limited and practical. There is a case of losing value.
또한, 전술한 티옥트산류의 지질류에 의한 피복물은, 이것을 음료 등의 수계 조성물에 적용하는 경우의 유무에 관계없이, 또한 그 외표면을 친수계 물질로 피복하여 이루어지는 형태의 것이 한층 더 바람직하다. 여기서, 친수계 물질이란 지질류에 의한 피복물의 외표면을 더 피복하고, 수성 물질과 친화성을 갖는 피복막 형성능이 있는 것을 말하며, 구체예로서 다당류(크산탄 검, 구아 검, 타마린드 시드 검, 사일륨 시드 검 등), 전분 및 화공 전분, 효모 세포벽 성분, 글루칸, 만난, 셰락, 알긴산 소다, 젤라틴, 카라기난, 풀루란, 카르복시메틸셀룰로오스, 대두단백, 훼이단백, 제인 등을 들 수 있다. 보다 적합하게는 다당류, 전분, 효모 세포벽 성분, 셰락, 젤라틴, 대두단백, 제인 및 만난으로부터 이루어지는 군에서 선택되는 1종 또는 2종 이상이고, 더욱 바람직하게는 효모 세포벽 성분, 셰락 및 젤라틴으로 이루어지는 군에서 선택되는 1종 또는 2종 이상이다.In addition, the coating material by the lipids of the thioctic acid mentioned above is more preferable in the form which coat | covers the outer surface with a hydrophilic substance, whether or not this is applied to aqueous compositions, such as a beverage, and is more preferable. . Here, the hydrophilic substance means that the outer surface of the coating by the lipids is further coated, and that the hydrophilic substance has a coating film forming ability having affinity with the aqueous substance, and as a specific example, polysaccharides (xanthan gum, guar gum, tamarind seed gum) And silium seed gums), starch and chemical starch, yeast cell wall components, glucan, mannan, sherak, soda alginate, gelatin, carrageenan, pullulan, carboxymethylcellulose, soy protein, whey protein, zein and the like. More preferably one or two or more selected from the group consisting of polysaccharides, starches, yeast cell wall components, sherak, gelatin, soy protein, zein and mannan, and more preferably a group consisting of yeast cell wall components, chelac and gelatin It is 1 type or 2 or more types chosen from.
이러한 친수계 물질에 의해 피복하기 위해서는 상기한 지질류의 피복 방법에 준한 방법을 채택하면 된다. 즉, 상기 친수계 물질을 적절하게 물, 에탄올, 그 밖의 용매에 용해시킨 액상물로 하고, 이것을 미리 지질류로 피복한 티옥트산류의 외표면에 부착, 건조하여 친수계 물질의 피복막을 형성시킬 수 있다. 이러한 피복물은 친수계 물질을 최외층으로 하는 이중 피복 구조체가 되고, 이것을 음식품, 사료, 화장품, 의약품 등에 이용하는 경우, 수성의 원료나 성분과의 친화성이 높아지고, 이들과 수용해성이 낮은 티옥트산류와의 균질한 조성물을 제조하는 것이 용이해진다.In order to coat | cover with such a hydrophilic substance, what is necessary is just to adopt the method according to the coating method of the said lipids. That is, the hydrophilic material is suitably dissolved in water, ethanol, and other solvents, and is attached to the outer surface of thioctic acid, which is previously coated with lipids, and dried to form a coating film of hydrophilic material. Can be. Such a coating becomes a double-coated structure having a hydrophilic substance as the outermost layer, and when used in foods, feeds, cosmetics, medicines, etc., the affinity with aqueous raw materials and components is high, and these are low in water solubility. It becomes easy to produce a homogeneous composition with acids.
전술한 바와 같은 티옥트산류의 지질류에 의한 피복물 및 상기 피복물을 친수계 물질로 더 피복한 이중 피복물에 있어서는, 이들에 가르시니아 캄보지아 과피, 아카쇼마 근경, 구아바 잎 및 이들의 추출물(물 및/또는 친수성 유기 용매(에탄올 등의 저급 1가 알코올, 아세톤 등)에 의한 추출 엑기스, 그 분획물이나 용제 분별물 또는 정제물 등), 카르니틴으로 이루어지는 군에서 선택되는 1종 또는 2종 이상, 보다 바람직하게는 아카쇼마 근경 추출물 및 카르니틴, 가장 바람직하게는 카르니틴을 병용하여 공존시킴으로써 티옥트산류의 열적 및/또는 산화적 변성이나 열화를 보다 한층 억제할 수 있어 안정성이 우수한 티옥트산류 함유 피복물이 얻어지기 때문에, 이러한 형태의 티옥트산류는 본 발명에 있어서 더욱 바람직하다.In the coating by the lipids of the thioctic acids as described above and the double coating in which the coating is further coated with a hydrophilic substance, these include Garcinia cambogia rind, Akashoma rhizome, Guava leaf and extracts thereof (water and / or One or two or more selected from the group consisting of extraction extracts with hydrophilic organic solvents (lower monohydric alcohols such as ethanol, acetone, etc.), fractions thereof, solvent fractions or purified products), and carnitine, more preferably Since coexistence of the akasoma rhizome extract and carnitine, and most preferably carnitine in combination, it is possible to further suppress thermal and / or oxidative denaturation and deterioration of thioctic acids, thereby obtaining a thioctic acid-containing coating having excellent stability. Thioctic acids of this type are more preferred in the present invention.
이들 병용 원료를 전술한 티옥트산류 함유 피복물에 함유시키는 형태는, (ⅰ) 티옥트산류의 결정, 분말 및/또는 입자에 지질류를 피복한 피복물에 상기 병용 원료를 혼합하는, (ⅱ) 티옥트산류의 결정, 분말 및/또는 입자와 상기 병용 원료를 혼합한 것에 지질류를 피복하는, (ⅲ) 티옥트산류의 결정, 분말 및/또는 입자에 상기 병용 원료의 일부를 분산 또는 용해시킨 지질류를 피복하는, (ⅳ) 티옥트산류의 결정, 분말 및/또는 입자에 지질류를 피복한 피복물에 상기 병용 원료 및 상기 친수계 물질을 포함하는 용해액, 분산액 또는 유화액을 부착, 건조하여 피복하는 것 모두 가능하고, 이들 형태를 조합한 것이어도 지장없다. 본 발명에서는 (ⅰ) 및 (ⅳ)의 형태가 본 발명의 원하는 효과를 발휘하고, 제조가 간편하고, 피복물의 취급 작업성도 좋지만, (ⅰ) 및 (ⅲ)의 형태가 원하는 효과를 보다 강력하게 발현하기 쉽다.The form which contains these combined raw materials in the above-mentioned thioctic acid containing coating material (i) mixes the said combined raw material with the coating which coat | covered lipids to the crystal | crystallization, powder, and / or particle | grains of thioctic acid (ii) tea (I) a lipid in which a part of the combined raw material is dispersed or dissolved in crystals, powder and / or particles of thioctic acid, which coat lipids with a mixture of crystals, powders and / or particles of oct acids and the above-mentioned raw materials. (I) attaching and drying a solution, a dispersion or an emulsion containing the concomitant raw material and the hydrophilic substance to a coating of lipids to crystals, powders and / or particles of thioctic acid, which is coated with It is possible to do both, and it does not interfere even if it combines these forms. In the present invention, the forms of (i) and (iii) exhibit the desired effects of the present invention, are easy to manufacture, and the handling workability of the coating is also good, but the forms of (iii) and (iii) provide the desired effect more strongly. Easy to express
이러한 형태에 있어서 티옥트산류의 결정, 분말 및/또는 입자에 지질류 또는 지질류 및 친수계 물질을 피복한 피복물과 상기 병용 원료의 혼합 비율은, 상기 피복물 1질량부에 대하여 상기 병용 원료가 약 0.01 내지 약 10질량부, 보다 바람직하게는 약 0.1 내지 약 1질량부이다. 약 0.01질량부 미만의 경우에는 병용 원료의 혼합에 의한 원하는 효과의 향상이 인정되지 않게 되고, 약 10질량부를 초과하는 양에서는 상기 피복물 중 나아가서는 이것을 사용하는 조성물 중의 티옥트산 함량이 저하되고, 나아가서는 티옥트산류 함유 조성물을 배합하는 각종 제품 중의 티옥트산 함량을 제한하게 되어, 상기 제품 단계에 있어서 티옥트산 자체의 원하는 효과를 기대할 수 없게 된다.In such a form, the mixing ratio of the coating material in which crystals, powders and / or particles of thioctic acid is coated with lipids or lipids and hydrophilic substances and the combination raw material is about 1 part by mass of the coating material. 0.01 to about 10 parts by mass, more preferably about 0.1 to about 1 part by mass. In the case of less than about 0.01 parts by mass, the desired improvement of the effect by mixing of the combined raw materials is not recognized, and in an amount exceeding about 10 parts by mass, the thioctic acid content in the above-mentioned coating and further in the composition using the same decreases, and furthermore, To limit the content of the thioctic acid in the various products incorporating the thioctic acid-containing composition, the desired effect of the thioctic acid itself in the product step can not be expected.
본 발명에 따른 레스베라트롤류의 기원이나 종류는 특별히 한정되는 것은 아니며, 공지된 유기 화학적인 방법 또는 미생물이나 효모 등을 이용하여 채취·제조된 것이면 되는데, 포도과, 여뀌과 또는 콩과 등의 식물의 과피, 줄기, 잎, 덩굴, 새싹, 종자, 꽃, 열매 등의 부위로부터 추출하여 얻어지는 것임이 바람직하다.The origin or type of resveratrol according to the present invention is not particularly limited, and may be one obtained and manufactured using known organic chemical methods or microorganisms or yeasts, and the skins of plants such as grapes, perillas and legumes, It is preferable that it is obtained by extracting from site | parts, such as a stem, a leaf, a vine, a sprout, a seed, a flower, and a fruit.
본 발명에 따른 레스베라트롤류의 기원으로서 보다 바람직한 식물은 포도과 포도속의 식물이며, 그 품종은 특별히 한정되는 것은 아니지만, 예를 들어 아이 렌, 알리고테, 발디구이, 비오니에, 벨슈리슬링, 오르테가, 까베르네 쇼비뇽, 까베르네 프랑, 가메, 카리냥, 가르가네가, 까르미네르, 시노마브로, 그뤼너 벨트리너, 게뷔르츠트라미너, 케르너, 고슈, 콜롬바드, 쌩소, 사그란티노, 산지오베제, 생로랑, 샤슬라, 샤르도네, 슈냉 블랑, 쇼이레베, 세미용, 쇼비뇽 블랑, 타낫, 츠바이겔트, 템프라니요, 트라미너, 돌체토, 돈펠더, 피노 뫼니에, 풀사르, 푸르민트, 포르투기저, 머스캣, 말바시아, 말벡, 뮈스카델, 뮐러 투르가우, 무르베드르, 멜론, 모리오 무스카토, 무스카딘, 아무르 포도, 아키 퀸, 비달 블랑, 거봉, 세토 자이언츠, 세이블 블랑, 델라웨어, 나이아가라, 네오머스캣, 바코 누아르, 바코 블랑, 피오네, 머스캣베일리, 후지미노리, 루비 로망, 카이지, 고슈산샤쿠 등을 들 수 있다. 이들은 일본, 칠레, 이탈리아, 프랑스 등에서 자생하거나 또는 재배되고 있는 것을 적절하게 이용하면 되며, 상기 예시한 품종의 각 부위, 보다 바람직하게는 줄기, 덩굴, 새싹 또는 꽃으로부터 추출하는 것이 좋다.Plants more preferred as the origin of the resveratrol according to the present invention are grapes and grape plants, the variety of which is not particularly limited, but for example, irene, aligote, valdigui, bionier, velshlithling, ortega, Cabernet Sauvignon, Cabernet Franc, Gamer, Carignan, Garganega, Carmine, Sinomabro, Grüner Beltliner, Gebürztraminer, Kerner, Gauche, Colombobad, Musso, Sagrandino, San Giuseppe, Saint Laurent , Shasla, Chardonnay, Schnean Blanc, Shorebe, Semiillon, Sauvignon Blanc, Tanat, Zweigelt, Tempranillo, Traminer, Dolceto, Donfelder, Pino Mönier, Fulsar, Purmint, Portugieser, Mus Cat, Malvasia, Malbec, Muscatel, Müller Thurgau, Murbedre, Melon, Morio Muscato, Muscadine, Amur Grape, Aquiquine, Vidal Blanc, Geobong, Seto Giants, Sable Blanc, Delaware, Na Niagara can be cited Neo Muscat, Bacau Noir, Blanc Bacau, Kuopio Yes, Muscat Bailey, Fuji Minori, ruby romance, Kaiji, Vail sansya ku, etc. These may be appropriately used those that are native or cultivated in Japan, Chile, Italy, France and the like, and are preferably extracted from each part of the above-mentioned varieties, more preferably stems, vines, buds or flowers.
본 발명에 따른 레스베라트롤류는 임의의 방법으로 제조하는 것이 가능한데, 상기 예시한 포도의 줄기, 덩굴, 새싹 또는 꽃 그 자체 또는 그들을 건조, 세단, 분쇄 처리한 것을 이용하고, 이들을 용매로 일정 기간 침지하거나, 또는 가열 환류하고 있는 추출 용매와 접촉시켜 추출액을 얻고, 상기 추출액으로부터 용매를 제거한 추출물, 상기 추출물에 실리카 겔, 규산마그네슘, 이온 교환 수지, 활성 알루미나, 셀룰로오스, 활성탄 등의 흡착제를 이용한 칼럼 크로마토그래피나 용제 분별 등의 정제 처리를 실시한 정제물 및 이들을 동결 건조, 분무 건조 등의 방법으로 분말화한 것의 어느 것이어도 된다. 식품 용도로 사용하는 경우에는 상기 식물의 부위를 건조하여 적절하게 분쇄한 분말, 상기 건조물의 세단편이나 분말을 물 또는 친수성 유기 용매로 추출한 추출물로 하는 것이 편리성이나 제조 비용의 점에서 바람직하다. 또한, 의약품 용도에 이용하는 경우에는 상기한 추출액, 추출물 또는 고순도의 정제물이 바람직하다.Resveratrol according to the present invention can be produced by any method, using the stems, vines, shoots or flowers of the above-described grapes themselves or those dried, shredded, ground, and soaked in a solvent for a certain period of time, Or by contacting with a heated reflux extraction solvent to obtain an extract, column chromatography using an adsorbent such as silica gel, magnesium silicate, ion exchange resin, activated alumina, cellulose, activated carbon, etc. (B) Any of the purified products subjected to the purification treatment such as solvent separation and powdered thereof by a method such as freeze drying or spray drying may be used. In the case of food use, it is preferable from the point of convenience or manufacturing cost that it is made into the powder which dried the site | part of the said plant, the powder | pulverization appropriately and the three fragments or powder of the dried product extracted with water or a hydrophilic organic solvent. Moreover, when using for a pharmaceutical use, said extract, said extract, or the purified product of high purity is preferable.
친수성 유기 용매로서 메탄올, 에탄올, 프로판올, 이소프로판올 등의 저급 1가 알코올류, 프로필렌글리콜, 1,3-부탄디올, 글리세린 등의 다가 알코올류, 아세톤, 메틸에틸케톤, 에테르, 석유 에테르, 아세트산에틸 및 이들의 함수물이나 혼합물을 예시할 수 있다. 본 발명의 원하는 효과를 발휘하기 위한 추출물을 효율적으로 얻기 위해서는 에탄올, 아세톤, 아세트산에틸 및 이들의 함수물을 추출용 용매로 하는 것이 바람직하다. 함수물의 수분 함량은 예를 들어 에탄올의 경우에서는 약 1 내지 약 99질량%, 보다 바람직하게는 약 50질량% 이하이고, 아세톤의 경우에는 약 1 내지 약 50질량%, 보다 바람직하게는 약 10 내지 약 30질량%이고, 아세트산에틸의 경우에는 약 80 내지 약 99질량%, 보다 바람직하게는 약 85 내지 약 95질량%이다. 이들 범위를 벗어나면 본 발명의 원하는 효과가 감소하거나 또는 추출물의 수량이 저하된다.Lower monohydric alcohols such as methanol, ethanol, propanol, isopropanol, polyhydric alcohols such as propylene glycol, 1,3-butanediol, glycerin, acetone, methyl ethyl ketone, ether, petroleum ether, ethyl acetate and the like as a hydrophilic organic solvent Examples of the water or mixture of In order to efficiently obtain the extract for achieving the desired effect of the present invention, it is preferable to use ethanol, acetone, ethyl acetate, and their water-containing products as the extraction solvent. The water content of the water is, for example, about 1 to about 99% by mass, more preferably about 50% by mass or less for ethanol, about 1 to about 50% by mass for acetone, and more preferably about 10 to It is about 30 mass%, and in the case of ethyl acetate, it is about 80 to about 99 mass%, More preferably, it is about 85 to about 95 mass%. Outside these ranges, the desired effect of the present invention is reduced or the yield of the extract is lowered.
본 발명에 따른 레스베라트롤류는 t-레스베라트롤(레스베라트롤의 단량체), 또는 ε-비니페린(이량체), 미야베놀 C(삼량체) 등의 중합체 및 이들의 이성체 및/또는 배당체 등의 스틸벤계 화합물을 대상으로 한다. 또한, 상기 식물로부터 얻어지는 추출물의 경우에는 상기 스틸벤계 화합물을 주된 활성 성분으로 하여 켈세틴, 엘라기탄닌, 엘라그산, 미네랄류(예를 들어 칼륨, 칼슘, 인, 마그네슘), 비타민류를 포함하는 경우가 있다.Resveratrol according to the present invention is a t-resveratrol (monomer of resveratrol), or polymers such as ε-viniferin (dimer), miyabenol C (trimer), and stilbene compounds such as isomers and / or glycosides thereof. It is targeted. In the case of the extract obtained from the plant, when the stilbene-based compound is used as the main active ingredient, it contains Kelcetin, ellagitannin, ellagic acid, minerals (for example, potassium, calcium, phosphorus and magnesium) and vitamins. There is.
본 발명의 피부 미용 촉진제에 있어서 콜라겐 펩티드와 병용하는 혈류 개선제의 함유량은 상기 제 전체의 약 0.01 내지 약 50질량%이고, 바람직하게는 약 0.1 내지 약 20질량%이고, 더욱 바람직하게는 약 0.5 내지 약 10질량%이다. 약 0.01질량%를 하회하면 병용에 의한 효과가 작고, 반대로 약 50질량%를 초과하는 사용도 추가의 원하는 효과는 기대할 수 없다. 또한, 혈류 개선제는 전술한 공지된 물질이나 추출물을 단독 또는 복수로 임의로 이용할 수 있는데, 바람직한 것은 동백나무 종자 추출물, 티옥트산류, 레스베라트롤류 및 레스베라트롤류를 함유하는 식물 추출물 중으로부터 선택되는 1종 또는 2종 이상이고, 더욱 바람직한 것은 이들을 모두 함유하는 것이다. 동백나무 종자 추출물, 티옥트산류, 레스베라트롤류 및 레스베라트롤류를 함유하는 식물 추출물 중 2종류 이상을 병용하는 경우의 비율(질량 기준)은 대강 동백나무 종자 추출물/티옥트산류가 20/80 내지 30/70, 보다 바람직하게는 60/40 내지 40/60이고, 동백나무 종자 추출물/레스베라트롤류가 99/1 내지 30/70, 보다 바람직하게는 80/20 내지 50/50이고, 티옥트산류/레스베라트롤류가 99/1 내지 30/70, 보다 바람직하게는 80/20 내지 50/50이고, 또한 동백나무 종자 추출물/티옥트산류/레스베라트롤류는 각각의 혈류 개선제의 비율이 피부 미용 촉진제 전체의 약 1질량% 이상, 보다 바람직하게는 약 10질량% 이상 함유하는 것이 바람직하다. 또한, 레스베라트롤류를 함유하는 식물 추출물의 경우에는 당해 추출물 중의 레스베라트롤류의 함량을 고려하여 설정하면 된다.In the skin care promoter of the present invention, the content of the blood flow improving agent used in combination with the collagen peptide is about 0.01% to about 50% by mass of the whole agent, preferably about 0.1% to about 20% by mass, more preferably about 0.5% to about 0.5%. It is about 10 mass%. If it is less than about 0.01 mass%, the effect by combined use is small, On the contrary, even if it uses more than about 50 mass%, the further desired effect cannot be expected. In addition, the blood flow improving agent may be optionally used alone or in a plurality of the known substances or extracts described above, preferably one or more selected from plant extracts containing camellia seed extract, thioctic acid, resveratrol and resveratrol. It is two or more types, and it is more preferable to contain all these. The ratio (mass basis) when using two or more types of plant extracts containing camellia seed extract, thioctic acid, resveratrol and resveratrol is about 20/80 to 30 / 70, more preferably 60/40 to 40/60, camellia seed extract / resveratrol is 99/1 to 30/70, more preferably 80/20 to 50/50, thioctic acid / resveratrol Is 99/1 to 30/70, more preferably 80/20 to 50/50, and the Camellia seed extract / Tioctanes / Resveratrol has a ratio of each blood flow improving agent to about 1 mass of the entire skin beauty promoter. It is preferable to contain% or more, More preferably, about 10 mass% or more. In addition, what is necessary is just to set in consideration of the content of the resveratrol in the said extract in the case of the plant extract containing resveratrol.
전술한 피부 미용 촉진제는 콜라겐 펩티드와 혈류 개선제 특히 동백나무 종자 추출물, 티옥트산류, 레스베라트롤류 및 레스베라트롤류를 함유하는 식물 추출물로 이루어지는 군으로부터 선택되는 1종 또는 2종 이상의 병용물을 유효 성분으로 하여, 이것을 그대로 즉 상기 유효 성분만을 포함하여 이루어지는 분말 형상, 고형 형상, 페이스트 상태 또는 액체 상태의 형태로 하고, 이것을 음식품, 의약품, 의약부외품, 사료 등의 용도에 이용하는 것이 가능하다.The above-mentioned skin care promoter is composed of one or two or more combinations selected from the group consisting of collagen peptides and blood flow improving agents, especially plant extracts containing camellia seed extract, thioctic acid, resveratrol and resveratrol as active ingredients. This may be used as it is, in the form of a powder, solid, paste or liquid form containing only the active ingredient, and used for foods, medicines, quasi-drugs, feeds and the like.
본 발명의 피부 미용 촉진제는 또한 이것이 이용될 수 있는 상기 용도에 있어서의 공지된 첨가물을 적절하게 병용하여 통상법에 의해 함유시켜 경구용 조성물로서 이용할 수도 있다. 여기서, 공지된 첨가물은 경구 섭취하기 위해서 통상 이용되는 것이면 되며, 예를 들어 부형제, 결합제, 붕괴제, 활택제, 습윤제, 유동화제, 보존제, 계면 활성제, 안정제, 희석제, 용해제, 등장화제, 살균제, 방부제, 교미제, 교취제, 착색제, 향료 등의 첨가 물질을 사용할 수 있다. 나아가서는 상기한 선행 기술 문헌에 기재된 것에 한정되지 않고, 피부 미용 작용 및/또는 혈류 개선 작용을 갖는 기지 성분이나 그 함유 소재를 병용하여도 된다. 본 발명의 피부 미용 촉진제는 또한 음식품, 의약품, 의약부외품, 사료, 그 밖의 산업 분야의 각종 제품의 배합 원료의 일부로서 사용할 수도 있다. 특히, 미용 등을 위한 제품으로 하는 것이 바람직하다.The skin care promoter of the present invention can also be used as an oral composition by appropriately using a well-known additive in the above-mentioned use in which it can be used, by conventional methods. Here, the known additives may be those commonly used for oral ingestion, for example, excipients, binders, disintegrants, lubricants, wetting agents, glidants, preservatives, surfactants, stabilizers, diluents, solubilizers, isotonic agents, fungicides, Additives, such as a preservative, a copper, a dentifier, a coloring agent, a fragrance | flavor, can be used. Furthermore, it is not limited to what was described in the said prior art document, You may use together a known component and its containing material which have a skin beauty action and / or a blood flow improving effect. The skin care promoter of the present invention can also be used as part of a blended raw material for foods, pharmaceuticals, quasi-drugs, feeds, and other products in the industrial field. In particular, it is preferable to set it as a product for beauty etc.
본 발명의 피부 미용 촉진제를 공지된 첨가물과 병용하여 경구용 조성물로 하는 경우의 형태는, 분말제, 과립제, 정제, 캅셀제, 액제 등의 타입의 경구용 제제로 하는 것이 가능하다.The form in the case of using the skin care promoter of the present invention in combination with a known additive to form an oral composition can be an oral preparation of a type such as powder, granule, tablet, capsule, liquid or the like.
이러한 경구용 조성물에 있어서의 상기 유효 성분의 함유량은, 병용하는 원료의 종류나 함유량 등에 따라 일률적으로 규정하기 어렵지만, 대강 0.1 내지 100질량% 정도, 보다 바람직하게는 약 10 내지 약 100질량%이다. 상기 함유량이 약 0.1질량%를 하회하면 본 발명의 원하는 효과가 인정되지 않게 된다. 본 발명의 피부 미용 촉진제는 이것을 경구적으로 섭취 또는 투여하는 방법으로 이용한다. 이 경우의 본 발명의 경구용 조성물의 바람직한 섭취량 또는 투여량의 기준은, 상기 제에 포함되는 상기 유효 성분 베이스로 인간 성인(체중 50kg) 1일당 약 100mg 내지 약 100,000mg, 바람직하게는 약 500mg 내지 약 10,000mg, 더욱 바람직하게는 약 1,000mg 내지 약 5,000mg이다.Although content of the said active ingredient in such an oral composition is hard to regulate uniformly according to the kind, content, etc. of the raw material to be used together, it is about 0.1-100 mass%, More preferably, it is about 10-100 mass%. When the said content is less than about 0.1 mass%, the desired effect of this invention will no longer be recognized. The skin care promoter of the present invention is used by the method of orally ingesting or administering it. In this case, the preferred intake or dosage criteria of the oral composition of the present invention is from about 100 mg to about 100,000 mg, preferably from about 500 mg per day, to a human adult (50 kg body weight) based on the active ingredient base included in the agent. About 10,000 mg, more preferably about 1,000 mg to about 5,000 mg.
본 발명의 피부 미용 촉진제는 이것을 음식품, 의약품, 의약부외품, 사료 등의 공지된 제품의 배합 원료의 일부로서 이용할 수 있다. 실용적인 제품의 예를 이하에 설명하는데, 본 발명은 이 예시에 의해 전혀 제한되는 것이 아니다.The skin beauty promoter of the present invention can be used as part of the compounding raw material of known products such as food and drink, medicine, quasi-drug and feed. Examples of practical products are described below, but the present invention is not limited at all by this example.
음식품의 구체예로서 야채 쥬스, 과즙 음료, 청량 음료, 차 등의 음료류; 케이크 프리믹스 제품, 빵, 케이크, 쿠키, 초콜렛, 캔디, 구미젤리, 검 등의 과자류; 된장, 간장, 소스, 마요네즈, 불고기용 소스나 국수 소스 등의 조미료; 즉석 국수, 우동, 메밀, 스파게티 등의 국수 종류; 햄이나 소세지 등의 축육 어육 가공 식품; 우유, 요구르트, 크림, 버터, 스프레드나 치즈 등의 분말 형상, 고형 형상 또는 액상의 유제품; 후리가케, 햄버거, 고로케, 조림(佃煮), 잼, 수프, 젤리, 푸딩, 드레싱, 식물성 크림, 마가린 등의 각종 일반 가공 식품 외에, 분말 형상, 과립 형상, 환약 형상, 정제 형상, 소프트 캡슐 형상, 하드 캡슐 형상, 페이스트 상태 또는 액체 상태의 영양 보조 식품, 특정 보건용 식품, 기능성 식품, 건강 식품, 농후 유동식이나 연하 장해용 식품의 치료식 등을 들 수 있다.As a specific example of food-drinks, Beverages, such as vegetable juice, fruit juice drink, a soft drink, tea; Confectionery such as cake premix products, breads, cakes, cookies, chocolates, candies, gummi jelly and gums; Seasonings such as miso, soy sauce, sauce, mayonnaise, bulgogi sauce and noodle sauce; Noodle varieties such as instant noodles, udon noodles, buckwheat and spaghetti; Meat and meat processed foods such as ham and sausages; Powdered, solid or liquid dairy products such as milk, yoghurt, cream, butter, spread or cheese; Powder form, granule form, pill form, pill form, tablet form, soft capsule form, hard food, as well as various general processed foods such as furikake, hamburger, croquette, stewed foods, jam, soup, jelly, pudding, dressing, vegetable cream and margarine Nutritional supplements in the form of capsules, pastes or liquids, specific health foods, functional foods, health foods, rich liquid foods, and therapeutic foods for swallowing disorders.
이들 음식품을 제조하기 위해서는 본 발명의 피부 미용 촉진제와 공지된 원재료를 이용하거나, 또는 공지된 원재료의 일부를 본 발명의 피부 미용 촉진제로 치환하고, 통상법에 의해 제조하면 된다. 예를 들어 본 발명의 피부 미용 촉진제를 필요에 따라 글루코오스, 포도당, 덱스트린, 유당, 전분 또는 그 가공물, 셀룰로오스 분말 등의 부형제, 비타민류, 미네랄류, 동식물이나 어개류의 유지, 단백(동식물이나 효모 유래의 단백질, 그 가수분해물 등을 포함함), 당질, 색소, 향료, 산화 방지제, 계면 활성제, 그 밖의 식용 첨가물, 각종 영양 기능 성분을 포함하는 분말이나 엑기스류 등의 식용 소재와 함께 혼합하여 분말, 과립, 펠릿, 정제 등의 형상으로 가공하거나, 통상법에 의해 상기 예의 일반 가공 식품의 형태로 가공하거나, 혼합한 분말이나 액상물을 젤라틴, 알긴산나트륨, 카르복시메틸셀룰로오스 등의 피복제로 피복하여 캡슐로 성형하거나, 음료(드링크류)의 형태로 가공하여 영양 보조 식품이나 건강 식품으로서 이용하는 것은 바람직하다. 특히, 정제, 캅셀제나 드링크제의 형태가 바람직하다. 또한, 이들 음식품에 포함되는 본 발명의 피부 미용 촉진제의 함량이나 섭취량은 전술한 경구용 조성물의 경우와 거의 마찬가지이다.In order to manufacture these food-drinks, the skin beauty promoter of this invention and a well-known raw material may be used, or a part of well-known raw materials may be substituted by the skin beauty promoter of this invention, and may be manufactured by a conventional method. For example, according to the skin beauty promoter of the present invention, if necessary, excipients such as glucose, glucose, dextrin, lactose, starch or processed products thereof, cellulose powder, vitamins, minerals, fats and oils of animals and plants, fish and protein (derived from plants and yeasts) Protein, hydrolyzate thereof, and the like), sugars, pigments, flavorings, antioxidants, surfactants, other food additives, mixed with food materials such as powders or extracts containing various nutritional functional ingredients, It is processed into the shape of granules, pellets, tablets, or the like, or processed into the form of general processed foods by the conventional method, or the mixed powder or liquid is coated with a coating agent such as gelatin, sodium alginate, carboxymethylcellulose, and formed into capsules. Or, it is preferable to process it in the form of a drink (drinks), and to use it as a nutritional supplement or a health food. In particular, the form of a tablet, a capsule, or a drink is preferable. In addition, the content and intake amount of the skin care promoter of the present invention contained in these food and drink are almost the same as in the case of the oral composition described above.
본 발명의 피부 미용 촉진제를 이용하는 의약품 및 의약부외품은, 상기한 경구 피부 미용 촉진제에 본 발명의 취지에 어긋나지 않는 범위에서 약학적으로 허용되는 공지된 부형제나 첨가물을 적절히 첨가하고, 통상법에 의해 가공하여 정제, 캅셀제, 과립제, 산제, 액제 등의 제제로 할 수 있다. 이것을 경구 투여하여 건조, 탄력 저하, 피부 거칠어짐 등의 예방 또는 치료를 위하여 적용한다. 또한, 이들 의약품 및 의약부외품에 포함되는 본 발명의 피부 미용 촉진제의 함량이나 섭취량은 전술한 경구용 조성물의 경우에 준한다.The medicines and quasi-drugs using the skin care promoter of the present invention are appropriately added to known oral excipients and additives to the oral skin care promoter described above within the scope of the present invention, and processed by a conventional method. Formulations, such as a tablet, a capsule, a granule, powder, and a liquid, can be used. It is orally administered and applied for the prevention or treatment of dryness, decreased elasticity, rough skin, and the like. In addition, the content and intake amount of the skin care promoter of the present invention contained in these medicines and quasi-drugs are in the case of the oral composition described above.
또한, 본 발명의 피부 미용 촉진제를 동물 음식이나 가축용 사료에 적용하기 위해서는, 상기 음식품의 경우와 마찬가지로 공지된 각종 사료나 음용수에 배합하거나 공지된 원재료, 첨가물과 함께 정제 형상, 과립 형상, 캡슐 형상 등의 제제 형태의 것으로 가공할 수 있다. 이들 사료에 있어서의 본 발명의 피부 미용 촉진제의 함량이나 섭취량은 전술한 경구용 조성물의 경우와 거의 마찬가지이다.In addition, in order to apply the skin care promoter of the present invention to animal food or animal feed, it is formulated in the same manner as in the case of the food and drink, or blended in various known feeds or drinking water, or in the form of tablets, granules, capsules with known raw materials and additives. It can be processed into a thing of the form of formulations, such as a shape. The content and intake amount of the skin care promoter of the present invention in these feeds are almost the same as in the case of the oral composition described above.
<실시예><Examples>
다음으로 실시예를 들어 본 발명을 상세하게 설명하는데, 본 발명은 이에 의해 전혀 한정되는 것은 아니다. 각 예에 있어서, %, 부 및 비율은 특별히 표시하지 않는 한 질량 기준이다.Next, although an Example is given and this invention is demonstrated in detail, this invention is not limited at all by this. In each example,%, part, and a ratio are a mass reference | standard unless there is particular notice.
제조예 1(콜라겐 펩티드 (1))Preparation Example 1 (Collagen Peptide (1))
메기의 몸 및 뼈를 제거한 가죽 1kg에 물 5L를 첨가하고, 상압하, 85℃로 가열하여 1시간 적절하게 교반하여 젤라틴을 추출하였다. 젤라틴 용액을 50℃까지 냉각하고, 단백질 분해 효소를 첨가하고, 2시간 효소 반응시켰다. 그 후, 효소를 실활시키고, 여과하여 여과액을 분리하였다. 여과액을 감압하에 농축하고, 동결 건조 및 분쇄하여 콜라겐 펩티드(시료 1)를 192g 얻었다. 이 콜라겐 펩티드를 통상법에 의해 HPLC 분석한 결과, 평균 분자량은 약 1,000이었다.5L of water was added to 1 kg of the catfish and the skin from which the bone was removed, and the mixture was heated to 85 ° C. under normal pressure and stirred for 1 hour to extract gelatin. The gelatin solution was cooled to 50 ° C, proteolytic enzymes were added, and enzymatic reaction was carried out for 2 hours. Thereafter, the enzyme was deactivated and filtered to separate the filtrate. The filtrate was concentrated under reduced pressure, lyophilized and triturated to give 192 g of collagen peptide (Sample 1). HPLC analysis of this collagen peptide by a conventional method found that the average molecular weight was about 1,000.
제조예 2(콜라겐 펩티드 (2))Preparation Example 2 (Collagen Peptide (2))
틸라피아의 비늘을 0.1N의 염산으로 처리한 후, 다량의 물로 세정하고, 햇볕 건조시켰다. 건조 비늘 1kg에 물 8L를 첨가하고, 상압하, 85℃로 가열하여 1시간 적절하게 교반하여 젤라틴을 추출하였다. 젤라틴 용액을 50℃까지 냉각하고, 단백질 분해 효소를 첨가하고, 1시간 효소 반응시켰다. 그 후, 효소를 실활시키고, 여과하여 여과액을 분리하였다. 여과액을 감압하에 농축하고, 동결 건조 및 분쇄하여 콜라겐 펩티드(시료 2)를 711g 얻었다. 이 콜라겐 펩티드를 통상법에 의해 HPLC 분석한 결과, 평균 분자량은 약 5,000이었다.The scales of tilapia were treated with 0.1 N hydrochloric acid, then washed with a large amount of water and dried in the sun. 8 L of water was added to 1 kg of dry scales, and the mixture was heated to 85 DEG C under normal pressure, stirred for 1 hour, and extracted with gelatin. The gelatin solution was cooled to 50 degreeC, the proteolytic enzyme was added, and the enzyme reaction was carried out for 1 hour. Thereafter, the enzyme was deactivated and filtered to separate the filtrate. The filtrate was concentrated under reduced pressure, lyophilized and triturated to give 711 g of collagen peptide (Sample 2). HPLC analysis of this collagen peptide by a conventional method found that the average molecular weight was about 5,000.
제조예 3(동백나무 종자 추출물 (1))Preparation Example 3 (camellia seed extract (1))
이즈오오시마산 야생동백나무의 건조 종자를 조분쇄하여 삶은 후, 압착하여 압착 오일을 분리한 압착박을 얻었다. 이 탈지물 1kg에 물 3L를 첨가하고, 상압하, 85℃로 가열하여 1시간 적절하게 교반한 후, 실온까지 냉각하고, 여과하여 여과액을 분리하였다. 이 여과 잔사에 다시 물 1L를 첨가하여 마찬가지로 가열, 교반, 냉각 후, 여과하여 여과액을 채취하였다. 양 여과액을 합하여 감압하에 농축하고, 동결 건조 및 분쇄하여 수용성 성분을 포함하여 이루어지는 분말 형상의 동백나무 종자 추출물(시료 3) 170g을 얻었다. 이 추출물은 이것을 통상법에 의해 HPLC 분석한 결과, 카멜리아사포닌 B2를 7.5%, 카멜리아사포닌 C2를 5.8%, 플라보놀의 1종인 캠퍼롤을 2.4% 포함하는 것이었다.The dried seeds of Izu Oshima wild camellia were coarsely crushed and boiled, and then compressed to obtain a compressed foil from which the compressed oil was separated. 3 L of water was added to 1 kg of this degreased substance, and it heated at 85 degreeC under normal pressure, stirred suitably for 1 hour, cooled to room temperature, filtered, and isolate | separated the filtrate. 1 L of water was further added to this filtration residue, and similarly it heated, stirred, and cooled, and filtered and collected the filtrate. Both filtrates were combined, concentrated under reduced pressure, lyophilized and pulverized to obtain 170 g of a powdery camellia seed extract (sample 3) comprising a water-soluble component. HPLC analysis of this extract by the conventional method showed that 7.5% of camelia saponin B2, 5.8% of camelia saponin C2, and 2.4% of camphorol, one of flavonols, were included.
제조예 4(동백나무 종자 추출물 (2))Preparation Example 4 (camellia seed extract (2))
제조예 3과 마찬가지로 처리하여 얻은 탈지물 1kg에 함수 에탄올(함수율 35%) 2L를 첨가하고, 80℃에서 1시간 가열 환류한 후, 실온까지 냉각하고, 여과하여 여과액을 분리하였다. 이 여과 잔사에 다시 함수 에탄올(함수율 35%) 2L를 첨가하여 마찬가지로 가열하고, 냉각 후, 여과하여 여과액을 채취하였다. 양 여과액을 합하여 감압하에 농축하고, 동결 건조 및 분쇄하여 수용성 성분을 포함하는 분말(시료 4) 12.1g을 얻었다. 상기 분말을 제조예 3과 마찬가지로 HPLC 분석한 결과, 카멜리아사포닌 B2를 8.3%, 카멜리아사포닌 C2를 5.9%, 플라보놀의 1종인 캠퍼롤을 2.6% 포함하는 것이었다.2 L of hydrous ethanol (35% water content) was added to 1 kg of the degreased product obtained in the same manner as in Production Example 3, heated to reflux at 80 ° C for 1 hour, cooled to room temperature, filtered, and the filtrate was separated. 2 L of hydrous ethanol (water content 35%) was added to this filtration residue again, it heated similarly, and after cooling, it filtered and collected the filtrate. Both filtrates were combined, concentrated under reduced pressure, lyophilized and ground to give 12.1 g of a powder (sample 4) containing a water-soluble component. HPLC analysis of the powder was carried out in the same manner as in Preparation Example 3, and found to contain 8.3% of Camellia saponin B2, 5.9% of Camellia saponin C2, and 2.6% of camphorol, one of flavonols.
제조예 5(티옥트산의 지질 피복물)Preparation Example 5 Lipid Coatings of Thioctic Acid
결정 분말의 티옥트산(독일·알츠켐사제, 상품명: 알리퓨어(ALIPURE)(등록 상표), 라세미체) 330g에 가열 용융한 유채씨 경화유(가와켄파인케미칼(주)제, 융점: 67℃, 플레이크 형상) 200g을 첨가하고, 잘 혼합하여 균일하게 분산시킨 후, 실온에서 냉각 고화시켰다. 계속해서, 상기 고화물을 고속 믹서로 분쇄하고, 100메쉬(타일러 메쉬. 이하 동일함)의 체로 쳐서 입자 직경이 150㎛ 이하인 티옥트산 지질 피복물 (시료 5)을 얻었다.Rapeseed seed hardened oil (Kawaken Fine Chemicals Co., Ltd. product) melting | fusing point: 330 g of crystallized titanic acid (made by Alzchem, Germany, brand name: ALIPURE (trademark), racemate) And 200 g of flakes were added, mixed well and uniformly dispersed, and then cooled and solidified at room temperature. Subsequently, the solid was pulverized with a high speed mixer and sieved with a 100 mesh (Tileer Mesh. Hereinafter identical) to obtain a thioctic acid lipid coating (Sample 5) having a particle diameter of 150 µm or less.
제조예 6(티옥트산의 시클로덱스트린 포접물)Preparation Example 6 (cyclodextrin inclusions of thioctic acid)
결정 분말의 티옥트산(독일·알츠켐사제, 상품명: ALIPURE(등록 상표), 라세미체) 100g을 50% 에탄올 500mL에 용해시키고, α-시클로덱스트린(독일·와카헤미사제, 상품명: 카바맥스(CAVAMAX)(등록 상표) (R)W6) 800g을 첨가하고, 적절하게 교반한 후, 농축, 분무 건조시켜 티옥트산시클로덱스트린 포접물(시료 6)을 얻었다.Dissolve 100 g of the thioctic acid (manufactured by Alzchem, Germany, trade name: ALIPURE (registered trademark), racemic body) of the crystal powder in 500 mL of 50% ethanol, and α-cyclodextrin (manufactured by Waka Hemi Co., Ltd., trade name: Carbamax ( 800 g of CAVAMAX (registered trademark) (R) W6) was added, and after stirring appropriately, it was concentrated and spray-dried to obtain a cyclodextrin tetrathiocate (sample 6).
제조예 7(레스베라트롤 추출물)Preparation Example 7 (Resveratrol Extract)
포도(까베르네 쇼비뇽종)의 줄기의 천일 건조물 500g을 2L의 70% 에탄올 용액으로 환류 추출한 후, 여과하여 여과액을 분리하였다. 이 여과액 잔사에 다시 70% 에탄올을 1L 첨가하여 환류 추출하고, 여과하여 여과액을 분리하였다. 양 여과액을 합하여 감압하에 농축하고, 거기에 덱스트린을 첨가하여 분무 건조하여 레스베라트롤 추출 분말(시료 7)을 24g 얻었다. 상기 분말을 통상법으로 HPLC 분석한 결과, 트랜스 레스베라트롤을 6.2%, ε-비니페린을 6.0% 포함하는 것이었다.500 g of the sun dried product of the stem of grape (cabernet Sauvignon species) was extracted with reflux with 2 L of 70% ethanol solution, and the filtrate was separated by filtration. 1 L of 70% ethanol was further added to the filtrate residue to extract reflux, and the filtrate was separated. Both filtrates were combined, concentrated under reduced pressure, and dextrin was added thereto, followed by spray drying to obtain 24 g of resveratrol extract powder (sample 7). HPLC analysis of the powder by conventional methods revealed that 6.2% of trans resveratrol and 6.0% of epsilon-viniferin were included.
시험예 1(혈류 개선 작용)Test example 1 (blood flow improvement effect)
이하에 설명하는 시험에 참가하는 것에 동의가 얻어진 피험자 40명(24 내지 65세, 남성 20명, 여성 20명)을 1군 5명으로 나누어 이중 맹검법에 의해 혈류 측정 시험을 행하였다. 우선, 피험자를 온도 24±2℃, 습도 50±10%에 제어한 항온·항습의 방에 입실시키고, 10분간 안정하게 대기시켰다. 이후, 시험 시료를 섭취하기 전의 손등의 혈류량을 레이저 도플러(페리메드(Perimed)사제, 페리스캔(PeriScan) PIMⅡ)를 이용하여 측정하였다. 이어서, 대조군(플라세보군)에는 피험자가 색으로 판별할 수 없도록 착색한 하드 캡슐(젤라틴제. 이하 마찬가지임)에 덱스트린을 충전한 것을, 그 밖의 군에는 상기 마찬가지로 착색한 하드 캡슐에 각 시험 시료를 충전한 것을 각각 물 100mL와 함께 섭취하게 하고, 30분 후, 60분 후에 다시 상기와 마찬가지로 손등의 혈류량을 측정하였다. 또한, 시험 시료는 상기한 동백나무 종자 추출물(시료 3, 시료 4), 시판하고 있는 티옥트산, 티옥트산 지질 피복물(시료 5), 레스베라트롤 추출물(시료 7), 시판하고 있는 은행나무 잎 추출물(비에이치엔(주)제) 및 당근 엑기스(마루젠제약(주)제)로 하였다.Forty subjects (24-65 years old, 20 males, 20 females) obtained consent to participate in the test described below were divided into five groups in one group, and blood flow measurement tests were performed by a double blind method. First, the subject was placed in a room of constant temperature and humidity controlled at a temperature of 24 ± 2 ° C. and a humidity of 50 ± 10%, and stably waited for 10 minutes. Thereafter, the blood flow of the back of the hand before taking the test sample was measured using a laser Doppler (manufactured by Perimed, PeriScan PIMII). Subsequently, the control group (the placebo group) was filled with dextrin in a colored hard capsule (gelatin, which is the same below) so that the subject could not discriminate by color, and in the other group, each test sample was put in the same colored hard capsule. Each of the fillings was ingested with 100 mL of water, and after 30 minutes, 60 minutes later, the blood flow of the back of the hand was measured as above. In addition, the test sample was a Camellia seed extract (Sample 3, Sample 4), commercially available thioctic acid, thioctic acid lipid coating (Sample 5), resveratrol extract (Sample 7), commercially available Ginkgo leaf extract (BH) It was set as En Co., Ltd., and carrot extract (made by Maruzen Pharmaceutical Co., Ltd.).
그 결과를 표 1에 나타낸다. 동 표에 있어서 수치는 플라세보 및 피험 물질을 섭취하기 전의 값을 100으로 하였을 때의 상대값으로서, 평균값±표준 편차로 나타냈다(n=5, ANOVA 해석). 표 1의 데이터로부터 플라세보를 섭취한 피험자의 손등 및 두피의 혈류량에는 유의한 변화는 인정되지 않았지만, 시료 3이나 시료 4(동백나무 종자 추출물), 티옥트산이나 시료 5(티옥트산 지질 피복물) 및 시료 7(레스베라트롤 추출물)을 섭취한 경우에는, 혈류 촉진 작용이 공지된 은행나무 잎 추출물이나 당근 엑기스를 섭취한 경우와 동일한 정도로, 섭취 30분 후 및 60분 후의 양 시간 모두 손등의 혈류량의 값이 유의미하게 높아지는 것을 확인하였다.The results are shown in Table 1. In the table, the numerical value is a relative value when the value before ingesting the placebo and the test substance is 100, and is represented by the mean value ± standard deviation (n = 5, ANOVA analysis). From the data in Table 1, no significant changes were observed in blood flow to the back and scalp of subjects who received placebo, but sample 3 or sample 4 (camellia seed extract), thioctic acid or sample 5 (thiocate lipid coating), and sample In the case of ingesting 7 (resveratrol extract), the blood flow value of the back of the hand was significant at both the 30 minutes and 60 minutes after ingestion to the same extent as when the ginkgo biloba leaf extract or carrot extract was known. It was confirmed that the increase.
[표 1] 손등의 혈류 촉진(혈류량)에 미치는 영향[Table 1] Effect on blood flow promotion (blood flow) on the back of the hand
시험예 2(피부 섬유아세포 증식 촉진 작용)Test Example 2 (skin fibroblast proliferation promoting action)
피부 섬유아세포의 증식에 미치는 영향을 이하의 방법으로 조사하였다. 즉, 페트리 접시(φ10cm)를 이용하고, 정상 인간 성인 피부 섬유아세포(구라보(주)제, NHDF(NB). 이하, 간단히 세포라고 함)를 10% 소 태아 혈청(다이이치화학약품(주)제) 첨가 D-MEM 배지(시그마사제, 저글루코오스)에 2×105개 뿌리고, 서브 콘플루언트(약 80% 밀도)가 될 때까지 4일간 배양하였다. 계속해서, 배지를 제거하고, 세포를 PBS 5mL로 2회 세정하고, 또한 0.02% EDTA 용액 5mL로 세정한 후, 0.25% 트립신 용액(나카라이테스크(주)제) 5mL를 이용하여 세포를 회수하고, 원심 분리(4℃, 1,000rpm, 5분)하여 상청을 제거하고, PBS로 2회 세정하여 세포를 얻었다. 이 세포를 상기 조건하에서 반복 배양하여 계대 배양하였다.The effect on the proliferation of skin fibroblasts was examined by the following method. In other words, a petri dish (φ10 cm) was used, and normal human adult skin fibroblasts (manufactured by Kurabo Industries, NHDF (NB), hereinafter simply referred to as cells) were subjected to 10% fetal bovine serum (Daiichi Chemical Co., Ltd.). ))) 2 × 10 5 was added to D-MEM medium (manufactured by Sigma Co., Ltd., low glucose), and cultured for 4 days until subconfluent (about 80% density) was obtained. Subsequently, the medium was removed, the cells were washed twice with 5 mL of PBS and further washed with 5 mL of 0.02% EDTA solution, and then the cells were collected using 5 mL of 0.25% trypsin solution (manufactured by Nakaray Tesque Co., Ltd.). Then, the supernatant was removed by centrifugation (4 ° C, 1,000 rpm, 5 minutes), and washed twice with PBS to obtain cells. These cells were subcultured by repeat culture under the above conditions.
96 구멍 세포 배양 플레이트(0.32cm2, 아사히테크노글래스(주)제)를 이용하여, 상기 계대 배양 세포를 인간 피부 섬유아세포 증식용 저혈청 배지(구라보(주)제, 피부 섬유아세포 기초 배지(106S) 500mL에 저혈청 증식 첨가제(LSGS) 10mL를 첨가한 배지) 중에 1×104개/웰 파종하고, 24시간 배양하였다. 계속해서, 배지를 제거하고, 최종 농도가 5, 10 또는 20μg/mL가 되도록 각 시료를 첨가한 상기 인간 피부 섬유아세포 증식용 저혈청 배지 중에서 48시간 더 배양을 계속하였다. 이 후, MTT 용액(티아졸릴블루테트라졸륨브로마이드(시그마사제, 시약)를 농도 5mg/mL로 용해한 PBS)을 25μL 첨가하여 1시간 배양하였다. 배지를 데칸테이션으로 완전히 제거한 후, 포르마잔 용액(25%(v/v) 0.45M 아세트산 완충액(pH4.5), 25%(v/v) N,N-디메틸포름아미드, 10%(w/v) n-도데실황산나트륨을 포함함, pH 4.5)을 100μL 첨가하여 교반하였다. 실온에서 하룻밤 방치 후, 590nm에 있어서의 흡광도를 측정하고, 세포의 증식 정도를 평가하였다. 또한, 상기 방법에 있어서 D-MEM 배지 및 인간 피부 섬유아세포 증식용 저혈청 배지는 페니실린(최종 농도 100IU/mL) 및 스트렙토마이신(최종 농도 0.1mg/mL)을 첨가한 것으로 하고, 세포 배양은 모두 CO2 인큐베이터(37℃, 5% CO2 강화 기상하)에서 행하였다. 또한, 시험 시료는 상기한 콜라겐 펩티드(시료 1, 시료 2), 동백나무 종자 추출물(시료 3, 시료 4), 시판하고 있는 티옥트산, 티옥트산 지질 피복물(시료 5), 티옥트산시클로덱스트린 포접물(시료 6), 레스베라트롤 추출물(시료 7), 시판하고 있는 은행나무 잎 추출물(비에이치엔(주)제), 당근 엑기스(마루젠제약(주)제) 및 시료 1 또는 시료 2와 각 시료의 병용으로 하였다.Using a 96-hole cell culture plate (0.32 cm 2 , manufactured by Asahi Techno Glass Co., Ltd.), the passaged cultured cells were cultured in low serum medium for human skin fibroblast growth (Kurabo Co., Ltd., skin fibroblast basal medium ( 106S) 1 × 10 4 cells / well were seeded in 500 mL of medium to which 10 mL of low serum growth additive (LSGS) was added), and cultured for 24 hours. Subsequently, the medium was removed, and further culture was continued for 48 hours in the low serum medium for human skin fibroblast proliferation to which each sample was added so as to have a final concentration of 5, 10 or 20 μg / mL. Thereafter, 25 µL of an MTT solution (PBS dissolved in thiazolyl blue tetrazolium bromide (manufactured by Sigma, Reagent) at a concentration of 5 mg / mL) was added thereto, followed by incubation for 1 hour. After complete removal of medium by decantation, formazan solution (25% (v / v) 0.45M acetic acid buffer (pH4.5), 25% (v / v) N, N-dimethylformamide, 10% (w / v) 100 μL of sodium n-dodecyl sulfate, pH 4.5) was added and stirred. After standing at room temperature overnight, the absorbance at 590 nm was measured, and the degree of proliferation of the cells was evaluated. In the above method, D-MEM medium and low serum medium for human skin fibroblast proliferation were added with penicillin (final concentration 100 IU / mL) and streptomycin (final concentration 0.1 mg / mL). It was carried out in a CO 2 incubator (37 ° C., 5% CO 2 enhanced gas phase). In addition, the test sample was the collagen peptide (Sample 1, Sample 2), Camellia seed extract (Sample 3, Sample 4), commercially available thioctic acid, thioctic acid lipid coating (Sample 5), and thioctic acid cyclodextrin clathrate. (Sample 6), Resveratrol extract (Sample 7), commercially available Ginkgo biloba leaf extract (made by BH Co., Ltd.), carrot extract (made by Maruzen Pharmaceutical Co., Ltd.), and sample 1 or 2 together with each sample It was made.
그 결과를 표 2, 표 3 및 표 4에 나타낸다. 동 표에 있어서 수치는 동시에 실시한 대조 시험(시료를 첨가하지 않은 경우)의 값을 100으로 하였을 때의 상대값으로 나타냈다. 표 2에 있어서, 시료 1과 시료 2는 최종 농도가 50 및 100μg/mL, 또한 그 밖의 시료는 최종 농도가 5 및 10μg/mL가 되도록 배지에 첨가하였다. 표 3 및 표 4에 있어서, 시료 1 및 시료 2는 50μg/mL로 하고, 그 밖의 시료를 5μg/mL씩 배지에 첨가하였다.The results are shown in Tables 2, 3, and 4. In the table, the numerical values are shown as relative values when the value of the control test (when no sample is added) conducted at the same time is 100. In Table 2, Samples 1 and 2 were added to the medium so that the final concentrations were 50 and 100 μg / mL, and the other samples had 5 and 10 μg / mL final concentrations. In Table 3 and Table 4, the sample 1 and the sample 2 were 50 micrograms / mL, and the other samples were added to the culture medium by 5 micrograms / mL.
표 2의 데이터로부터 각 첨가 농도에 있어서 각 시료는 피부 섬유아세포를 증식시키는 작용이 약하지만 인정되었다.From the data in Table 2, at each concentration of each sample, although the effect of proliferating skin fibroblasts was weak, it was recognized.
또한, 표 3의 데이터로부터 시료 1에 시료 3 내지 7 및 티옥트산을 병용한 경우, 상승적으로 섬유아세포를 증식시키는 작용이 명확해졌다. 또한, 시료 1과 시료 3, 시료 7 및 티옥트산을 병용함으로써 상기 증식 효과는 증강되었다. 그러나, 은행나무 잎 엑기스 및 당근 엑기스에서는 섬유아세포의 증식을 높이는 작용은 확인할 수 없었다.In addition, from the data in Table 3, when Samples 1 to 7 and thioctic acid were used in combination with Sample 1, the effect of synergistically proliferating fibroblasts became clear. Further, the proliferation effect was enhanced by using Sample 1, Sample 3, Sample 7, and Thioctic Acid in combination. However, the effect of enhancing the proliferation of fibroblasts could not be confirmed in the ginkgo leaf extract and carrot extract.
표 4의 데이터로부터도 섬유아세포의 증식을 높이는 작용을 확인하였으나, 표 3의 데이터의 경우보다도 당해 증식 효과는 낮은 경향이 인정되었다.Although the effect of raising the proliferation of fibroblasts was also confirmed from the data of Table 4, it was recognized that the proliferation effect was lower than that of the data of Table 3.
또한, 시료 1이나 시료 2 대신에 평균 분자량이 약 300인 콜라겐 펩티드를 이용하여 마찬가지로 시험한 결과, 병용물에 의한 섬유아세포 증식 촉진 효과는 표 3의 데이터의 경향과 동등 내지는 그 이상이었다(데이터 생략).In addition, as a result of similar tests using collagen peptides having an average molecular weight of about 300 instead of Sample 1 or Sample 2, the fibroblast proliferation promoting effect by the combination was equal to or more than the trend of the data in Table 3 (data omitted) ).
[표 2][Table 2] 각 시료가 피부 섬유아세포의 증식에 미치는 영향Effect of each sample on the proliferation of skin fibroblasts
[표 3] 시료 1과의 조합이 섬유아세포의 증식에 미치는 영향TABLE 3 Effect of combination with sample 1 on proliferation of fibroblasts
[표 4] 시료 2와의 조합이 섬유아세포의 증식에 미치는 영향TABLE 4 Effect of combination with sample 2 on proliferation of fibroblasts
이상으로부터 본 발명에 따른 콜라겐 펩티드와 혈류 개선제의 조합, 특히 동백나무 추출물, 티옥트산류, 레스베라트롤류에 의해 인간 피부 섬유아세포의 증식을 현저하게 촉진하는 작용이 있는 것이 명확해졌다.From the above, it has been clarified that the combination of the collagen peptide and the blood flow improving agent according to the present invention, in particular, the Camellia extract, the thioctic acid and the resveratrol, has a function of significantly promoting the proliferation of human skin fibroblasts.
또한, 시험 데이터는 생략하지만, 본 시험예에 있어서 시료 1 또는 시료 2와 상기 3종류의 혈류 개선 작용 성분을 병용한 경우에는 각각을 단독으로 이용한 경우에 비하여 인간 피부 섬유아세포에 의한 콜라겐 생산능 및 히알루론산 생산능이 현저하게 높아지는 것이 확인되었다.In addition, although test data is abbreviate | omitted, when the sample 1 or the sample 2 and the said three types of blood flow improving action components are used together in this test example, compared with the case where each was used alone, the collagen production ability by human skin fibroblasts, It was confirmed that the hyaluronic acid production capacity is remarkably high.
시험예 3(인간에 있어서의 피부 미용 시험)Test example 3 (skin beauty test in human)
이하에 설명하는 시험에 참가하는 것에 동의가 얻어진 피부 탄력성 및 수분량이 저하된 자원봉사의 성인 여성 60명(35세 내지 55세, 평균연령:48.6세)에게, 1군 5명으로 나누어 각각의 군에 각 시료를 섭취하게 하고, 이것을 6주간 계속하였다. 시료를 섭취하기 전후에서 피부 탄력성에 대하여 피부 점탄성 측정 장치(독일, 커리지+카자카(Courage+Khazaka)사, 제품명: 커토미터(CUTOMETER) MPA580(R))를 이용하여 측정하고, 또한 얼굴의 일정 부위의 수분에 대하여 수분 측정 장치(코르네오미터(Corneometer)(R)CM825)를 이용하여 수분 상대값을 측정하였다. 또한, 본 시험은 상기한 시료 1, 시료 3, 시료 7, 티옥트산 및 이들의 조합, 상기와 마찬가지의 은행나무 잎 엑기스로 행하였다. 섭취량은 시료 1이 5g, 그 이외의 시료는 200mg으로 하고, 시료 1과의 조합의 경우, 시료 1이 5g, 그 이외의 시료는 200mg의 병용으로 하였다.60 adult women (35 to 55 years old, average age: 48.6 years old) of volunteers whose skin elasticity and moisture content were reduced to consent to participate in the test described below were divided into 5 groups of 1 group each Each sample was taken and continued for 6 weeks. Skin viscoelasticity measuring device (Courage + Khazaka, Germany, product name: CUTOMETER MPA580 (R)) was measured for skin elasticity before and after sample ingestion. The relative moisture of the site was measured using a moisture measuring device (Corneometer (R) CM825). In addition, this test was done by the sample 1, the sample 3, the sample 7, thioctic acid, these combinations, and the same ginkgo leaf extract which were mentioned above. The intake amount was 5 g of sample 1 and 200 mg of the other samples, and in combination with sample 1, 5 g of sample 1 and 200 mg of other samples were used together.
그 결과를 표 5에 나타낸다. 시료를 섭취하기 전후에서의 피부 탄력성 및 수분량은 은행나무 잎 엑기스 이외의 각 시료를 섭취한 경우, 섭취 전과 비교하여 섭취 후에서는 약간의 개선 작용이 보여졌지만, 섭취 전과 큰 차는 없었다. 그러나, 시료 1과 각각을 조합한 경우, 피부 탄력성 및 수분량은 명백하게 개선되고, 본 발명에 따른 콜라겐 펩티드와 혈류 개선제의 조합, 특히 동백나무 추출물, 티옥트산류, 레스베라트롤류와의 병용에 의해 피부 미용 작용을 현저하게 촉진하는 작용이 있는 것이 명확해졌다.The results are shown in Table 5. The skin elasticity and water content before and after taking the sample showed a slight improvement after the intake of each sample other than the Ginkgo biloba extract, but there was no significant difference before and after the intake. However, in the case of combining each of Sample 1, the skin elasticity and moisture content are obviously improved, and the skin beauty is achieved by the combination of the collagen peptide and the blood flow improving agent according to the present invention, in particular in combination with Camellia extract, thioctal acid and resveratrol. It is clear that there is a function that significantly promotes the action.
[표 5] 인간의 피부에 미치는 영향 (평균값±표준 오차) [Table 5] Effect on human skin (mean value ± standard error)
시작예 1(소프트 캡슐)Starting example 1 (soft capsule)
상기한 시료 1 및 시료 3(혼합비:10/1), 시료 1 및 시료 7(혼합비:10/1), 시료 1 및 티옥트산(혼합비:10/1), 시료 1 및 시료 3 및 시료 7 및 티옥트산(혼합비:10/1/1/1) 중 어느 1종: 200부에 밀랍: 40부 및 달맞이꽃 오일(영국에파몰사제): 50부를 첨가하고, 가열 혼합하여 균질화 후, 캡슐 충전기에 제공하여 통상법에 의해 1알당 내용량이 250mg인 젤라틴 피복 소프트 캡슐 제제를 시작하였다. 이 캡슐 제제는 경구 섭취 가능한 영양 보조 식품, 의약품 또는 동물용 사료로서 이용할 수 있다.Sample 1 and Sample 3 (mixing ratio: 10/1), Sample 1 and Sample 7 (mixing ratio: 10/1), Sample 1 and thioctic acid (mixing ratio: 10/1), Sample 1 and Sample 3, and Sample 7 and One kind of thioctic acid (mixing ratio: 10/1/1/1): 200 parts of beeswax: 40 parts of beeswax and evening primrose oil (manufactured by UK EPA), added to the capsule filling machine after homogenization by heat mixing The gelatin-coated soft capsule formulation having a 250 mg content per tablet was started by a conventional method. This capsule formulation can be used as an orally ingestible nutritional supplement, medicine or animal feed.
시작예 2(하드 캡슐)Start example 2 (hard capsule)
시료 1 및 시료 3(혼합비:10/1), 시료 1 및 시료 4 및 시료 6(혼합비:10/3/1), 시료 1 및 시료 4 및 시료 7(혼합비:10/1/1), 시료 1 및 시료 4 및 시료 5 및 시료 7(혼합비:10/2/1/1) 중 어느 1종을 캡슐 충전기에 제공하여 통상법에 의해 1알당 내용량이 200mg인 젤라틴 피복 하드 캡슐 제제를 시작하였다. 이 캡슐 제제는 경구 섭취 가능한 영양 보조 식품, 의약품 또는 동물용 사료로서 이용할 수 있다.Sample 1 and Sample 3 (mixing ratio: 10/1), Sample 1 and Sample 4 and Sample 6 (mixing ratio: 10/3/1), Sample 1 and Sample 4 and Sample 7 (mixing ratio: 10/1/1), Sample Any one of 1 and Sample 4 and Sample 5 and Sample 7 (mixing ratio: 10/2/1/1) was provided to the capsule charger to start a gelatin-coated hard capsule formulation having a content of 200 mg per tablet by a conventional method. This capsule formulation can be used as an orally ingestible nutritional supplement, medicine or animal feed.
시작예 3(음료)Start example 3 (beverages)
시판하고 있는 영양 드링크 100mL에 시료 1 및 시료 3(혼합비:10/1), 시료 1 및 시료 7(혼합비:10/1), 시료 1 및 티옥트산(혼합비:10/1)의 각 1,000mg을 각각 첨가하여 충분히 혼합하여 음료를 시작하였다. 이것은 냉장고에서 6개월간 보존하여도 외관 및 풍미에 이상 및 위화감은 보이지 않았다. 본품은 건조, 탄력 저하, 피부 거칠어짐 등의 피부 상태의 개선 및/또는 피부 미용의 촉진을 위한 음료나 드링크제로서 이용할 수 있다.In 100 mL of commercially available nutritional drinks, 1,000 mg of each of Sample 1 and Sample 3 (mixing ratio: 10/1), Sample 1 and Sample 7 (mixing ratio: 10/1), Sample 1, and thioctic acid (mixing ratio: 10/1) Each was added and thoroughly mixed to start a drink. This preserved in the refrigerator for 6 months, did not show any abnormalities and discomfort in appearance and flavor. This product can be used as a beverage or a drink for improving skin conditions such as drying, lowering elasticity, rough skin, and / or promoting skin cosmetology.
<산업상 이용가능성>Industrial Applicability
본 발명의 콜라겐 펩티드와 상기 특정한 3종류의 혈류 개선제로부터 선택되는 1종 또는 2종 이상을 포함하여 이루어지는 병용물을 유효 성분으로서 포함하는 피부 미용 촉진제는, 이것을 경구로 섭취 또는 투여함으로써 피부의 건조, 탄력 저하, 피부 거칠어짐의 개선 및/또는 피부 미용을 촉진하는 작용을 갖기 때문에 음식품, 의약품, 의약부외품, 사료 등의 분야에 있어서 유효하게 이용할 수 있다.A skin beauty promoter comprising as an active ingredient a combination comprising a collagen peptide of the present invention and one or two or more selected from the above-described three kinds of blood flow improving agents, dry or dry the skin by orally ingesting or administering it. Since it has the effect | action which reduces elasticity, improves skin roughness, and / or promotes skin beauty, it can utilize effectively in the field of food-drinks, medicines, quasi-drugs, feeds, etc.
Claims (13)
A cosmetic method for improving skin condition such as drying of the skin, lowering of elasticity, roughness of the skin, and / or promoting skin beauty, characterized by orally ingesting the skin beauty promoter according to any one of claims 1 to 10. .
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JPJP-P-2011-114156 | 2011-04-28 | ||
JP2011114156 | 2011-04-28 | ||
PCT/JP2012/061191 WO2012147842A1 (en) | 2011-04-28 | 2012-04-26 | Beautiful-skin-promoting agent and use thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20140027947A true KR20140027947A (en) | 2014-03-07 |
KR101840508B1 KR101840508B1 (en) | 2018-03-20 |
Family
ID=47072357
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020137026500A KR101840508B1 (en) | 2011-04-28 | 2012-04-26 | Beautiful-skin-promoting agent and use thereof |
Country Status (5)
Country | Link |
---|---|
JP (1) | JP6205616B2 (en) |
KR (1) | KR101840508B1 (en) |
CN (2) | CN103501800B (en) |
TW (1) | TWI436774B (en) |
WO (1) | WO2012147842A1 (en) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101961152B1 (en) * | 2017-11-15 | 2019-03-25 | 주식회사 프롬바이오 | Food composition or cosmetics for whitening, moisturizing or anti-aging of skin with sheep placenta and plant complex |
KR20190031634A (en) | 2017-09-18 | 2019-03-27 | 진명종 | Anti-wrinkle and Anti-aging cosmetics compositions using colloidal gold |
US10722436B2 (en) | 2015-08-10 | 2020-07-28 | Mary Kay Inc. | Topical compositions |
KR20210047425A (en) | 2019-10-21 | 2021-04-30 | 코스맥스 주식회사 | Cosmetic Composition for Enhancing Skin |
KR20230096601A (en) | 2021-12-23 | 2023-06-30 | 주식회사 앤나코스메틱 | Serum cosmetics composition effective for anti-wrinkle and hypopigmentation containing gold grain |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP6022333B2 (en) * | 2012-12-11 | 2016-11-09 | 花王株式会社 | Ceramide production promoter |
JP6026257B2 (en) * | 2012-12-11 | 2016-11-16 | 花王株式会社 | Ceramide production promoter |
ES2791448T3 (en) | 2013-01-23 | 2020-11-04 | Bottled Science Ltd | Composition of drink to improve the skin |
KR101853927B1 (en) | 2016-08-12 | 2018-05-02 | 주식회사 제이 | A cosmetic composition comprising enzymatic hydrolysate of salmon scaled with the excellent effect of skin exfoliation efficacy, itching improvement and scalp dandruff improvemtny |
CN108719215A (en) * | 2018-03-28 | 2018-11-02 | 宜州市壮之都丝绸家纺有限公司 | A kind of high-yield cultivation method of silkworm |
TW202017586A (en) | 2018-06-29 | 2020-05-16 | 日商好侍健康食品股份有限公司 | Composition for improving vascular endothelical function or improving blood flow in peripheral blood vessels |
TWI824585B (en) * | 2022-06-27 | 2023-12-01 | 孟鄉生化科技股份有限公司 | Polymer film |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2256838T3 (en) * | 1993-10-11 | 2006-07-16 | VIATRIS GMBH & CO. KG | PREPARED FOR THE TREATMENT OF HYPERTENSION. |
JP4336486B2 (en) * | 2002-10-04 | 2009-09-30 | 一丸ファルコス株式会社 | Hyaluronic acid production promoter |
JP4076477B2 (en) * | 2003-05-28 | 2008-04-16 | 株式会社クラレ | Skin preparation |
JP4700313B2 (en) * | 2004-09-27 | 2011-06-15 | サントリーホールディングス株式会社 | Composition comprising proanthocyanidins and sphingolipids |
JP4253296B2 (en) * | 2004-12-16 | 2009-04-08 | 尚文 石川 | Health beauty food |
JP5016535B2 (en) * | 2008-03-27 | 2012-09-05 | 株式会社 資生堂 | Anti-aging food supplements and anti-aging agents |
JP4420357B1 (en) * | 2009-03-24 | 2010-02-24 | 株式会社資生堂 | Hyaluronic acid production promoter |
JP4420358B1 (en) * | 2009-03-27 | 2010-02-24 | 株式会社資生堂 | Hyaluronic acid production promoter |
JP4413272B1 (en) * | 2009-04-06 | 2010-02-10 | 株式会社資生堂 | Hyaluronic acid production promoter |
JP5685752B2 (en) * | 2009-05-13 | 2015-03-18 | ビーエイチエヌ株式会社 | Blood flow promoting agent |
JP2011195504A (en) * | 2010-03-19 | 2011-10-06 | Shiseido Co Ltd | Hyaluronic acid production promoter, anti-ageing agent and wrinkle-ameliorating agent |
JP2012067082A (en) * | 2010-08-23 | 2012-04-05 | Yuki Yamashita | Oral composition |
JP2012056919A (en) * | 2010-09-13 | 2012-03-22 | Shiseido Co Ltd | Hyaluronic acid production promotor |
JP2012121871A (en) * | 2010-12-10 | 2012-06-28 | Shiseido Co Ltd | Agent for improving skin barrier function |
-
2012
- 2012-04-26 WO PCT/JP2012/061191 patent/WO2012147842A1/en active Application Filing
- 2012-04-26 CN CN201280020408.4A patent/CN103501800B/en active Active
- 2012-04-26 CN CN201611137754.7A patent/CN107050438A/en active Pending
- 2012-04-26 JP JP2012115029A patent/JP6205616B2/en active Active
- 2012-04-26 KR KR1020137026500A patent/KR101840508B1/en active IP Right Grant
- 2012-04-27 TW TW101115224A patent/TWI436774B/en active
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10722436B2 (en) | 2015-08-10 | 2020-07-28 | Mary Kay Inc. | Topical compositions |
US11179305B2 (en) | 2015-08-10 | 2021-11-23 | Mary Kay Inc. | Topical compositions |
KR20190031634A (en) | 2017-09-18 | 2019-03-27 | 진명종 | Anti-wrinkle and Anti-aging cosmetics compositions using colloidal gold |
KR101961152B1 (en) * | 2017-11-15 | 2019-03-25 | 주식회사 프롬바이오 | Food composition or cosmetics for whitening, moisturizing or anti-aging of skin with sheep placenta and plant complex |
KR20210047425A (en) | 2019-10-21 | 2021-04-30 | 코스맥스 주식회사 | Cosmetic Composition for Enhancing Skin |
KR20230096601A (en) | 2021-12-23 | 2023-06-30 | 주식회사 앤나코스메틱 | Serum cosmetics composition effective for anti-wrinkle and hypopigmentation containing gold grain |
Also Published As
Publication number | Publication date |
---|---|
WO2012147842A1 (en) | 2012-11-01 |
CN107050438A (en) | 2017-08-18 |
CN103501800B (en) | 2017-01-18 |
TWI436774B (en) | 2014-05-11 |
JP2012236826A (en) | 2012-12-06 |
TW201300136A (en) | 2013-01-01 |
KR101840508B1 (en) | 2018-03-20 |
JP6205616B2 (en) | 2017-10-04 |
CN103501800A (en) | 2014-01-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101840508B1 (en) | Beautiful-skin-promoting agent and use thereof | |
EP1813309A1 (en) | Abnormal protein removing composition | |
JP4470212B2 (en) | Skin improver | |
WO2007148737A1 (en) | Method of preparing plant extract, plant extract and use of the same | |
JP2008280311A (en) | Prophylactic/curative agent for hyperlipemia | |
JP5685752B2 (en) | Blood flow promoting agent | |
JP2010202520A (en) | Skin improver and oral composition for cosmetic and health purposes | |
WO2016163245A1 (en) | Activator of energy metabolism in muscle cells | |
JP2010095529A (en) | Composition for improving lipid metabolism | |
US20130252923A1 (en) | Skin-beautifying agent | |
JP2006160685A (en) | Oral agent for preventing or ameliorating skin aging | |
JP4420357B1 (en) | Hyaluronic acid production promoter | |
JP2008308505A (en) | Composition for removing abnormal protein | |
JP2008239505A (en) | Neuroblast growth promoter and neurite extender | |
JP2005015364A (en) | Anti-oxidizing composition, skin ageing-preventing composition, anti-inflammatory composition and lipid metabolism-improving composition | |
JP2009269832A (en) | Calcitonin gene-related peptide and composition for accelerating production of insulin-like growth factor-1 | |
JP2012067082A (en) | Oral composition | |
JP2004331543A (en) | Fibroblast growth-promoting agent and skin cosmetic and beauty food or drink | |
JP2021143131A (en) | Anti-aging agent, skin cosmetic and oral composition | |
JP2015221760A (en) | Collagen synthetic promoter, hyaluronic acid synthetic promoter, and ceramide synthetic promoter | |
JP4332778B2 (en) | Transparency base and its use | |
KR102525595B1 (en) | Health food composition containing fish collagen | |
JP6629036B2 (en) | Skin cosmetics and foods and drinks | |
JP5798289B2 (en) | Abnormal protein removal composition | |
JP2021063053A (en) | Agent for reducing environmental pollutant damage, cosmetic and food and drink |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
A302 | Request for accelerated examination | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right |